トップ›研究者一覧›八木健太

研究者を探す

研究者にアプローチする
更新情報を通知する

八木健太

徳島大学

プロフィール
教育活動
研究活動
社会活動
リサーチマップ・
Jグローバル
KAKEN
注目研究

研究者総覧で最新データを確認する

2025年6月27日更新

職名: 医学部附属病院薬剤部准教授 / 副薬剤部長
電話: 研究者総覧に該当データはありませんでした。
電子メール: 研究者総覧に該当データはありませんでした。
学歴: 2014年1月1日〜2018年1月1日岡山大学大学院医歯薬総合研究科
2008年1月1日〜2014年1月1日岡山大学薬学部薬学科
学位: 博士 / 博士(医学) (岡山大学) (2018年)
職歴・経歴: 2020/4: 徳島大学特任助教, 病院 (-2024.3.)
2024/4: 徳島大学特任講師, 病院 (-2025.3.)

専門分野・研究分野: 医療薬学
臨床薬理学
薬理学
医療ビッグデータ

研究者総覧で最新データを確認する

2025年6月27日更新

専門分野・研究分野: 医療薬学
臨床薬理学
薬理学
医療ビッグデータ
担当経験のある授業科目: 研究者総覧に該当データはありませんでした。
指導経験: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2025年6月27日更新

専門分野・研究分野: 医療薬学
臨床薬理学
薬理学
医療ビッグデータ

研究テーマ: 研究者総覧に該当データはありませんでした。

著書

研究者総覧に該当データはありませんでした。

論文

Rie Ando-Matsuoka, Kei Kawada, Takahiro Niimura, Hitoshi Fukuda, Tomoaki Ishida, Toshihiko Yoshioka, Yu Kawanishi, Tomohito Kadota, Shinji Abe, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Tetsuya Ueba and Keisuke Ishizawa :
Risk factors for clazosentan-induced fluid retention in subarachnoid hemorrhage from the Japanese adverse event database,
Journal of Stroke & Cerebrovascular Diseases, 34, 6, 2025.

(キーワード): Cerebral vasospasm / Clazosentan / Fasudil / Subarachnoid hemorrhage
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.jstrokecerebrovasdis.2025.108296
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-105001481060

(DOI: 10.1016/j.jstrokecerebrovasdis.2025.108296, Elsevier: Scopus) Ayaka Nitta, Mitsuhiro Goda, Takahiro Niimura, Toshiki Kajihara, Maki Sato, Masayuki Chuma, Kei Kawada, Kaito Tsujinaka, Koji Miyata, Yuki Kono, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Rifampicin in combination treatments for methicillin-resistant staphylococcal prosthetic joint infections: Claims database evaluation using a cohort of 52,588 hip arthroplasty patients.,
International Journal of Clinical Pharmacology and Therapeutics, 2025.

(要約): Hip arthroplasty is a common surgical procedure effective for pain relief and maintaining walking function. Prosthetic joint infection (PJI) is a serious complication. Rifampicin combination therapy is widely used to treat PJIs caused by Staphylococcus aureus or coagulase-negative Staphylococcus, which are challenging to treat due to biofilm formation. However, its effectiveness is unclear. The effectiveness of anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics combined with rifampicin is also unclear.This study assessed the effectiveness and safety of MRSA antibiotics combined with rifampicin for treating methicillin-resistant staphylococcal PJI using a Japanese clinical database.This retrospective analysis used the claims database to examine data on PJI after hip arthroplasty among patients aged 20 years or older who were treated with anti-MRSA antibiotics, with or without rifampicin, from 2014 to 2021. The primary outcome was defined as no revision arthroplasty, while the safety outcomes were renal dysfunction and hypersensitivity.Among 52,588 patients who underwent hip replacement or artificial head insertion surgeries, 53 were treated for PJI with anti-MRSA antibiotics and received debridement, antibiotics, and implant retention, with 33 without rifampicin and 20 with rifampicin. The incidence of revision arthroplasty did not differ significantly between the two groups (3 vs. 5 patients; log-rank test, p = 0.195). The incidence of adverse events was similar between the two groups.In this analysis, rifampicin combination therapy provided no additional benefit in treating methicillin-resistant PJI after hip replacement surgery. If used together, close monitoring for the occurrence of adverse effects is advised.
(徳島大学機関リポジトリ): ● Metadata: 2013220
(出版サイトへのリンク): ● Publication site (DOI): 10.5414/CP204740
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40396698; ● Search Scopus @ Elsevier (PMID): 40396698; ● Search Scopus @ Elsevier (DOI): 10.5414/CP204740

(徳島大学機関リポジトリ: 2013220, DOI: 10.5414/CP204740, PubMed: 40396698) Kenta Yagi, Kajizono Makoto, Maruo Akinori, Shinmura Wataru, NItta Yuuki, Yoshioka Toshihiko, Masayuki Chuma, Ishida Shunsuke, Higashionna Tsukasa, Tanaka Hiroaki, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Kei Kawada, Yuki Izawa-Ishizawa, Yoshito Zamami, Kosaka Shinji, Tasaki Yoshikazu and Keisuke Ishizawa :
Effective drug dosage rounding reduces healthcare expenses in the Japanese healthcare system,
Drugs & Therapy Perspectives, 2025.

(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s40267-025-01144-6
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-105000760714

(DOI: 10.1007/s40267-025-01144-6, Elsevier: Scopus) Yuki Kono, Takahiro Niimura, Mitsuhiro Goda, Shiho Ueta, Kei Kawada, Koji Miyata, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Cardiovascular Toxicity Profile of Macrolides Investigated Using VigiBase Data: A Pharmacovigilance Study.,
Cardiovascular Toxicology, 25, 3, 498-506, 2025.

(要約): Macrolides are associated with cardiovascular toxicity risk. However, data on their cardiovascular toxicity profiles beyond QT prolongation are limited, and differences in the profiles among various macrolide antibiotics remain unclear. We investigated the cardiovascular toxicity profiles of different macrolides using VigiBase, a global database of individual case-safety reports. Disproportionality analysis was performed using VigiBase, the WHO Pharmacovigilance database, from 1968 to December 2023. Associations between five macrolides (erythromycin, clarithromycin, azithromycin, josamycin, and roxithromycin) and adverse events (20 cardiovascular toxicities and diarrhea as a positive control) were predicted using the reporting odds ratio. Reported outcomes were evaluated for suggested drug-adverse event associations. Among the 36,129,107 reports analyzed, azithromycin was the most commonly used macrolide, followed by erythromycin, clarithromycin, roxithromycin, and josamycin. Diarrhea was frequently reported among users. Azithromycin use was associated with hypertension, cardiac valve disorders, supraventricular tachyarrhythmias, ventricular tachyarrhythmias, torsade de pointes/QT prolongation, cardiac conduction disorders, heart failure, and hemorrhage-related laboratory abnormalities. Erythromycin and clarithromycin use were also associated with cardiac valve disorders, ventricular tachyarrhythmias, torsade de pointes/QT prolongation, and cardiac conduction disorders. The rates of caused/prolonged hospitalization in azithromycin-related hypertension, heart failure, and bleeding-related laboratory abnormality were 46%, 45%, and 50%, respectively. Each of the macrolide antimicrobials was associated with various cardiovascular toxicities, including Cardiac valve disorder, shock, and QT prolongation. Notably, azithromycin was associated with an increased frequency of reported hypertension and heart failure, distinguishing it from the other drugs. These results highlight the importance of considering the cardiovascular toxicity profile of individual macrolide antibiotics when prescribing them.
(キーワード): Macrolides / Pharmacovigilance / Adverse Drug Reaction Reporting Systems
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12012-025-09970-w
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39971867; ● Search Scopus @ Elsevier (PMID): 39971867; ● Search Scopus @ Elsevier (DOI): 10.1007/s12012-025-09970-w

(DOI: 10.1007/s12012-025-09970-w, PubMed: 39971867) Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Mitsuhiro Goda, Hideki Nawa, Yuya Horinouchi, Toshimi Nakamura, Harumasa Hakuno, Kazuaki Shinomiya, Yoshito Zamami, Masahiko Azuma, Masashi Akaike and Keisuke Ishizawa :
Assessing the effects of interprofessional education by hospital pharmacists on pharmaceutical students using a self-evaluation scale,
Journal of Pharmaceutical Health Care and Sciences, 10, 1, 61, 2024.

(要約): Understanding the roles and competencies of professions outside of one's specialty is essential for providing efficient healthcare. However, it is difficult for medical professionals to understand the roles and competencies of other related professions while performing their duties. This study examined the impact of clinical practice-based interprofessional education (IPE) on pharmacy students, who are future medical professionals. Sixty-eight pharmaceutical students undergoing clinical practice were divided into non-IPE or IPE groups, with the IPE group attending an educational program with medical students conducted by doctors, pharmacists, and teachers during the clinical practice period. The effect was evaluated through a group survey using self-administered questionnaires focusing on contributing to multidisciplinary team medicine based on the Readiness for Interprofessional Learning Scale. The survey included specific behavioral objectives (SBOs), the Readiness for Interpersonal Learning Scale (RIPLS), and Kikuchi's Scale of Social Skills (KiSS-18). Regardless of group, SBOs [non-IPE: 3.2, 95% CI (2.6-3.8), p < 0.001; IPE: 3.7, 95% CI (2.5-4.9), p < 0.001] and social skills [non-IPE: 4.0, 95% CI (2.5-6.1), p < 0.001; IPE: 6.7 95% CI (3.0-10.4), p < 0.001] showed improvement after the clinical practice. In RIPLS Factor 3, pharmacy students with IPE awareness scored significantly higher by 1.5 points [95% CI (0.2-2.8), p = 0.025] post-practice than those without IPE awareness. This study suggests that IPE for students during clinical practice could enhance their expertise in multidisciplinary medicine and facilitate the development of seamless team care in the future. This study was retrospectively registered and conducted in compliance with the "Ethical Guidelines for Medical Research Involving Human Subjects" and was approved by The Ethics Committee of Tokushima University Hospital (approval number: 3544).
(出版サイトへのリンク): ● Publication site (DOI): 10.1186/s40780-024-00382-6
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39354644; ● Search Scopus @ Elsevier (PMID): 39354644; ● Search Scopus @ Elsevier (DOI): 10.1186/s40780-024-00382-6

(DOI: 10.1186/s40780-024-00382-6, PubMed: 39354644) Fuka Aizawa, Haruna Kajimoto, Okabayashi Ami, Daishi Moriyama, Kenta Yagi, Takahashi Shimon, sonoda Yuhei, shibata Takahiro, Mitsuhiro Goda, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Kei Kawada, Yoshito Zamami and Keisuke Ishizawa :
Statins ameliorate oxaliplatin- and paclitaxel-induced peripheral neuropathy via glutathione-S-transferase,
Neurochemistry International, 180, 105863, 2024.

(要約): Some therapeutic agents have been found to have effects beyond their primary indications. Peripheral neuropathy, a common side effect of chemotherapy, remains inadequately treated. Identifying additional properties of existing medications could thus uncover novel therapeutic avenues. Previous studies have identified an additional effect of simvastatin in reducing neuropathy; however, the mechanism underlying this effect remains unclear. We investigated the novel effects of statins on chemotherapy-induced peripheral neuropathy in mice. Mice treated with oxaliplatin or paclitaxel did not show exacerbation or improvement in cold sensations upon acetone testing with statin administration. However, concurrent oral statin treatment mitigated the nociceptive response to mechanical stimuli induced by each anti-tumor agent. Co-administration of a glutathione S-transferase inhibitor, which modulates redox reactions, abolished the ameliorative effect of statins on mechanical nociceptive behavior. Additionally, the glutathione S-transferase inhibitor did not affect normal sensory perception or impair the anti-tumor effect of chemotherapy agents. A search for GST-associated molecules and pathways using artificial intelligence revealed that GST regulates inflammatory cytokines as a regulatory or causative gene. Our findings suggest that statins have class effects that ameliorate cytotoxic anti-cancer drug-induced mechanical allodynia via GST pathway activation.
(キーワード): Animals / Oxaliplatin / Paclitaxel / Peripheral Nervous System Diseases / Glutathione Transferase / Mice / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Male / Antineoplastic Agents / Mice, Inbred C57BL
(徳島大学機関リポジトリ): ● Metadata: 2012457
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.neuint.2024.105863
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39307458; ● Search Scopus @ Elsevier (PMID): 39307458; ● Search Scopus @ Elsevier (DOI): 10.1016/j.neuint.2024.105863

(徳島大学機関リポジトリ: 2012457, DOI: 10.1016/j.neuint.2024.105863, PubMed: 39307458) Koji Miyata, Yuki Izawa-Ishizawa, Kaito Tsujinaka, Honoka Nishi, Syuto Itokazu, Tatsumi Miyata, Masateru Kondo, Toshihiko Yoshioka, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Maki Sato, Mizusa Hyodo, Hirofumi Hamano, Kei Kawada, Masayuki Chuma, Yoshito Zamami, Koichi Tsuneyama, Mitsuhiro Goda and Keisuke Ishizawa :
Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments,
Biomedicine & Pharmacotherapy, 179, 117418, 2024.

(要約): Fluoroquinolones, which are widely used antibiotics, have been linked to aortic disease, which prompted an FDA warning in 2018. Recent reports have challenged the perception that fluoroquinolones pose a significant risk for vascular diseases. This study aimed to investigate whether fluoroquinolones increase the risk of aortic diseases by focusing on the onset of aortic dissection. Levofloxacin (LVFX), a fluoroquinolone, was studied in vitro using cultured vascular cells and in vivo using a mouse model prone to aortic dissection. Risk of adverse drug events was analyzed using VigiBase, a global safety database, and a retrospective cohort analysis was conducted using the JMDC Claims database. LVFX resulted in endothelial cell injury and increased matrix metalloproteinases in vitro. However, in vivo studies showed no significant effect on elastin degradation or aortic dissection incidence. The effect of LVFX on endothelial injury was altered during the onset of dissection, exacerbating injury before onset but inhibiting it afterward. Safety database analysis showed no significant risk signals for aortic dissection associated with fluoroquinolones, which was supported by findings in the receipt database. Inconsistencies were observed in the in vitro and in vivo actions of fluoroquinolones and differences in their effects on aortic dissection and aneurysms. Despite cytotoxicity, the risk of aortic dissection was not significantly increased in clinical scenarios. Based on our findings, concerns regarding aortic diseases do not justify discontinuation of fluoroquinolone use. Further studies are needed to elucidate the conflicting actions of fluoroquinolones, taking into account background pathophysiology such as infection and inflammation.
(キーワード): Aortic aneurysm / Aortic dissection / Endothelial cell injury / Fluoroquinolones / Real-world database
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.biopha.2024.117418
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39265233; ● Summary page in Scopus @ Elsevier: 2-s2.0-85203457086

(DOI: 10.1016/j.biopha.2024.117418, PubMed: 39265233, Elsevier: Scopus) Naoki Okamoto, Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Koji Miyata, Kei Kawada, Yuki Izawa-Ishizawa, Satoshi Sakaguchi and Keisuke Ishizawa :
Asciminib, A Novel Allosteric Inhibitor of BCR-ABL1, Shows Synergistic Effects When Used in Combination with Imatinib with or without Drug Resistance.,
Pharmacology Research & Perspectives, 12, 4, e1214, 2024.

(要約): In the treatment of chronic myeloid leukemia (CML), resistance to BCR-ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecular targeted drugs is useful to avoid drug resistance, the new BCR-ABL inhibitor asciminib and conventional BCR-ABL inhibitors should be used as monotherapy in principle. Therefore, we investigated the synergistic effect and mechanism of the combination of asciminib and imatinib. We generated imatinib-resistant cells using the human CML cell line K562, examined the effects of imatinib and asciminib exposure on cell survival using the WST-8 assay, and comprehensively analyzed genetic variation related to drug resistance using RNA-seq and real-time PCR. A synergistic effect was observed when imatinib and asciminib were combined with or without imatinib resistance. Three genes, GRRP1, ESPN, and NOXA1, were extracted as the sites of action of asciminib. Asciminib in combination with BCR-ABL inhibitors may improve the therapeutic efficacy of conventional BCR-ABL inhibitors and prevent the development of resistance. Its dosage may be effective even at minimal doses that do not cause side effects. Further verification of this mechanism of action is needed. Additionally, cross-resistance between BCR-ABL inhibitors and asciminib may occur, which needs to be clarified through further validation as soon as possible.
(キーワード): Imatinib Mesylate / Humans / Fusion Proteins, bcr-abl / Drug Synergism / Drug Resistance, Neoplasm / K562 Cells / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Protein Kinase Inhibitors / Cell Survival / Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents / Niacinamide / Pyrazoles
(徳島大学機関リポジトリ): ● Metadata: 2007994
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/prp2.1214
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39031848; ● Search Scopus @ Elsevier (PMID): 39031848; ● Search Scopus @ Elsevier (DOI): 10.1002/prp2.1214

(徳島大学機関リポジトリ: 2007994, DOI: 10.1002/prp2.1214, PubMed: 39031848) Midori Iida, Yurika Kuniki, Kenta Yagi, Mitsuhiro Goda, Satoko Namba, Jun-ichi Takeshita, Ryusuke Sawada, Michio Iwata, Yoshito Zamami, Keisuke Ishizawa and Yoshihiro Yamanishi :
A network-based trans-omics approach for predicting synergistic drug combinations,
Communications Medicine, 4, 1, 154, 2024.

(要約): Combination therapy can offer greater efficacy on medical treatments. However, the discovery of synergistic drug combinations is challenging. We propose a novel computational method, SyndrumNET, to predict synergistic drug combinations by network propagation with trans-omics analyses. The prediction is based on the topological relationship, network-based proximity, and transcriptional correlation between diseases and drugs. SyndrumNET was applied to analyzing six diseases including asthma, diabetes, hypertension, colorectal cancer, acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Here we show that SyndrumNET outperforms the previous methods in terms of high accuracy. We perform in vitro cell survival assays to validate our prediction for CML. Of the top 17 predicted drug pairs, 14 drug pairs successfully exhibits synergistic anticancer effects. Our mode-of-action analysis also reveals that the drug synergy of the top predicted combination of capsaicin and mitoxantrone is due to the complementary regulation of 12 pathways, including the Rap1 signaling pathway. The proposed method is expected to be useful for discovering synergistic drug combinations for various complex diseases.
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s43856-024-00571-2
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39075184; ● Search Scopus @ Elsevier (PMID): 39075184; ● Search Scopus @ Elsevier (DOI): 10.1038/s43856-024-00571-2

(DOI: 10.1038/s43856-024-00571-2, PubMed: 39075184) Kei Kawada, Tomoaki Ishida, Hitoshi Fukuda, Yuki Hyohdoh, Toru Kubo, Tomoyuki Hamada, Yuichi Baba, Toshinobu Hayashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Hiroaki Kitaoka and Keisuke Ishizawa :
Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan.,
Frontiers in Cardiovascular Medicine, 11, 2024.

(要約): = 0.246, respectively). These results suggest that beta blockers may differ in their all-cause mortality benefits according to age.
(徳島大学機関リポジトリ): ● Metadata: 2012787
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fcvm.2024.1377228
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38883984; ● Search Scopus @ Elsevier (PMID): 38883984; ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2024.1377228

(徳島大学機関リポジトリ: 2012787, DOI: 10.3389/fcvm.2024.1377228, PubMed: 38883984) Kei Kawada, Tomoaki Ishida, Shumpei Morisawa, Kohei Jobu, Youichirou Higashi, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda, Mitsuhiko Miyamura and Keisuke Ishizawa :
Atractylodes lancea (Thunb.) DC. [Asteraceae] rhizome-derived exosome-like nanoparticles suppress lipopolysaccharide-induced inflammation in murine microglial cells.,
Frontiers in Pharmacology, 15, 2024.

(要約): Exosome-like nanoparticles (ELNs) mediate interspecies intercellular communications and modulate gene expression. In this study, we isolated and purified ELNs from the dried rhizome of Atractylodes lancea (Thunb.) DC. [Asteraceae] (ALR-ELNs), a traditional natural medicine, and investigated their potential as neuroinflammatory therapeutic agents. ALR-ELN samples were isolated and purified using differential centrifugation, and their physical features and microRNA contents were analyzed through transmission electron microscopy and RNA sequencing, respectively. BV-2 microglial murine cells and primary mouse microglial cells were cultured , and their ability to uptake ALR-ELNs was explored using fluorescence microscopy. The capacity of ALR-ELNs to modulate the anti-inflammatory responses of these cells to lipopolysaccharide (LPS) exposure was assessed through mRNA and protein expression analyses. Overall, BV-2 cells were found to internalize ALR-ELNs, which comprised three microRNAs (ath-miR166f, ath-miR162a-5p, and ath-miR162b-5p) that could have anti-inflammatory activity. Pretreatment of BV-2 cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide, interleukin-1β, interleukin-6, and tumor necrosis factor-α. Notably, the mRNA levels of , and in BV-2 cells, which increased upon LPS exposure, were significantly reduced following ALR-ELN treatment. Moreover, the mRNA levels of heme oxygenase 1, , and also increased significantly following ALR-ELN treatment. In addition, pretreatment of primary mouse microglial cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide. Our findings indicate that ALR-ELNs exhibit anti-inflammatory effects on murine microglial cells. Further validation may prove ALR-ELNs as a promising neuroinflammatory therapeutic agent.
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fphar.2024.1302055
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38738173; ● Search Scopus @ Elsevier (PMID): 38738173; ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2024.1302055

(DOI: 10.3389/fphar.2024.1302055, PubMed: 38738173) Naoto Okada, Hirofumi Hamano, Kenta Yagi, Takahiro Niimura, Fuka Aizawa, Mitsuhiro Goda, Yoshito Zamami, Takashi Kitahara and Keisuke Ishizawa :
Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database.,
International Journal of Clinical Pharmacology and Therapeutics, 62, 2, 69-76, 2024.

(要約): A total of 353 patients were included, of which 61 were included in the ILD group. The median time to onset of ILD after ICI administration was 3 months. Multivariate logistic regression analysis revealed that pre-treatment with EGFR-TKI was not associated with ICI-associated ILD (odds ratio: 0.26, 95% confidence interval: 0.033 - 2.01).
(キーワード): Humans / Lung Neoplasms / Immune Checkpoint Inhibitors / Carcinoma, Non-Small-Cell Lung / Retrospective Studies / Japan / Lung Diseases, Interstitial / ErbB Receptors / Protein Kinase Inhibitors
(出版サイトへのリンク): ● Publication site (DOI): 10.5414/CP204491
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37969096; ● Search Scopus @ Elsevier (PMID): 37969096; ● Search Scopus @ Elsevier (DOI): 10.5414/CP204491

(DOI: 10.5414/CP204491, PubMed: 37969096) Koji Miyata, Yuki Izawa-Ishizawa, Takahiro Niimura, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Kei Kawada, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa :
The Association between PDE5 Inhibitors and Aneurysm/Arterial Dissection: A Pharmacovigilance Study Using WHO Safety Database,
The Journal of Medical Investigation : JMI, 71, 1-2, 134-140, 2024.

(要約): Aneurysm and arterial dissection have been reported as adverse drug events, associated with angiogenesis inhibitors and fluoroquinolones. Specifically, several cases of severe arterial disease following cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors usage have recently been reported. It is necessary to ascertain the risks of serious adverse events caused by PDE5 inhibitors. We aimed to evaluate the association of aneurysm and artery dissection with PDE5 inhibitors using VigiBase, which is a World Health Organization database of spontaneously reported adverse events, for explorative hypothesis-generating analysis. We performed disproportionality analysis using a dataset from inception in 1967 to December 2022 and calculated reporting odds ratios (ROR) between PDE5 inhibitors and arterial diseases. We extracted 195,839 reports on PDE5 inhibitors with 254 reports of arterial disease as adverse events from VigiBase. Disproportionality analysis showed disproportional signals for PDE5 inhibitors (ROR, 2.30;95% confidence intervals, 2.04-2.61);disproportional signals were detected in analyses restricting the lesion site to the aorta or cerebral arteries. From stratified analysis, disproportional signals were noted in females, as well as males, generally recognized as a risk factor for artery diseases. This real-world data analysis suggests that PDE5 inhibitors may play a role in the development of lethal arterial disease. J. Med. Invest. 71 : 134-140, February, 2024.
(キーワード): Adverse event / Aneurysm / Arterial dissection / PDE5 inhibitors / Pharmacovigilance
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.71.134
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38735709; ● Summary page in Scopus @ Elsevier: 2-s2.0-85192870665

(DOI: 10.2152/jmi.71.134, PubMed: 38735709, Elsevier: Scopus) Takashi Bando, Masayuki Chuma, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Masateru Kondo, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Yuki Izawa-Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa :
Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases.,
Acta Medica Okayama, 77, 6, 595-605, 2023.

(要約): There is a growing concern about the relationship between vancomycin-associated nephrotoxicity (VAN) and concomitant use of nephrotoxins. We examined this relationship by combined retrospective analyses of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was analyzed for the effects of concomitant use of one or more nephrotoxins on VAN and the types of combinations of nephrotoxins that exacerbate VAN. Next, electronic medical records (EMRs) of patients who received vancomycin (VCM) at Tokushima University Hospital between January 2006 and March 2019 were examined to confirm the FAERS analysis. An elevated reporting odds ratio (ROR) was observed with increases in the number of nephrotoxins administered (VCM + one nephrotoxin, adjusted ROR (95% confidence interval [CI]) 1.67 [1.51-1.85]; VCM + 2 nephrotoxins, adjusted ROR [95% CI] 1.54 [1.37-1.73]) in FAERS. EMRs analysis showed that the number of nephrotoxins was associated with higher incidences of VAN [odds ratio: 1.99; 95% CI: 1.42-2.78]. Overall, concomitant use of nephrotoxins was associated with an increased incidence of VAN, especially when at least one of those nephrotoxins was a renal hypoperfusion medication (furosemide, non-steroidal anti-inflammatory drugs, and vasopressors). The concomitant use of multiple nephrotoxins, especially including renal hypoperfusion medication, should be avoided to prevent VAN.
(キーワード): Humans / Vancomycin / Anti-Bacterial Agents / Retrospective Studies / Causality / Acute Kidney Injury
(徳島大学機関リポジトリ): ● Metadata: 2011484
(出版サイトへのリンク): ● Publication site (DOI): 10.18926/AMO/66151
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38145933; ● Search Scopus @ Elsevier (PMID): 38145933; ● Search Scopus @ Elsevier (DOI): 10.18926/AMO/66151

(徳島大学機関リポジトリ: 2011484, DOI: 10.18926/AMO/66151, PubMed: 38145933) Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, Koji Miyata, Takahiro Niimura, Hirofumi Hamano, Takumi Sakurada, Yoshito Zamami and Keisuke Ishizawa :
Valproic acid treatment attenuates cisplatin-induced kidney injury by suppressing proximal tubular cell damage.,
Clinical and Translational Science, 16, 11, 2369-2381, 2023.

(要約): Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods. Sodium valproic acid is a prophylactic drug candidate with a high potential for clinical application against cisplatin-induced kidney injury. Therefore, in this study, we aimed to elucidate the mechanism underlying the prophylactic effect of valproic acid on cisplatin-induced kidney injury in a mouse model and HK2 and PODO cells with cisplatin-induced toxicity. In the mouse model of cisplatin-induced kidney injury, various renal function parameters and tubular damage scores were worsened by cisplatin, but they were significantly improved upon combination with valproic acid. No difference was observed in cisplatin accumulation between the cisplatin-treated and valproic acid-treated groups in whole blood and the kidneys. The mRNA expression levels of proximal tubular damage markers, apoptosis markers, and inflammatory cytokines significantly increased in the cisplatin group 72 h after cisplatin administration but significantly decreased upon combination with valproic acid. In HK2 cells, a human proximal tubular cell line, the cisplatin-induced decrease in cell viability was significantly suppressed by co-treatment with valproic acid. Valproic acid may inhibit cisplatin-induced kidney injury by suppressing apoptosis, inflammatory responses, and glomerular damage throughout the kidneys by suppressing proximal tubular cell damage. However, prospective controlled trials need to evaluate these findings before their practical application.
(キーワード): Mice / Animals / Humans / Cisplatin / Valproic Acid / Prospective Studies / Acute Kidney Injury / Kidney / Apoptosis / Mice, Inbred C57BL
(徳島大学機関リポジトリ): ● Metadata: 2011485
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cts.13638
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37700528; ● Search Scopus @ Elsevier (PMID): 37700528; ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13638

(徳島大学機関リポジトリ: 2011485, DOI: 10.1111/cts.13638, PubMed: 37700528) Kaito Tsujinaka, Yuki Izawa-Ishizawa, Koji Miyata, Toshihiko Yoshioka, Kohei Oomine, Honoka Nishi, Masateru Kondo, Syuto Itokazu, Tatsumi Miyata, Takahiro Niimura, Maki Sato, Fuka Aizawa, Kenta Yagi, Masayuki Chuma, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa :
Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection.,
Biomedicine & Pharmacotherapy, 167, 2023.

(要約): Aortic dissection is an adverse event of angiogenesis inhibitors; however, the association between the drugs and aortic dissection is unclear. Therefore, we investigated if and how angiogenesis inhibitors increase the onset of aortic dissection using pharmacologically-induced aortic dissection-prone model (LAB) mice, cultured endothelial cells, and real-world databases, which is a novel integrated research approach. Disproportionality analysis was performed and calculated using the reporting odds ratio as a risk signal using a worldwide database of spontaneous adverse events to estimate the risk of adverse events. Angiogenesis inhibitors, but not other hypertension-inducing drugs, showed significant risk signals for aortic aneurysms and dissection. A retrospective cohort analysis using JMDC, a medical receipt database in Japan, showed that the history of atherosclerosis and dyslipidemia, but not hypertension, were significantly associated with the onset of aortic dissection during angiogenesis inhibitor medication administration. For in vivo studies, sunitinib (100 mg/kg/day) was administered to LAB mice. Sunitinib increased systolic blood pressure (182 mmHg vs. 288 mmHg with sunitinib; p<0.01) and the incidence of aortic dissection (40% vs. 59% with sunitinib; p = 0.34) in mice. In vivo and in vitro studies revealed that sunitinib increased endothelin-1 expression and induced endothelial cell damage evaluated by intracellular- and vascular cell adhesion molecule-1 expressions. The increased risk of developing aortic dissection with angiogenesis inhibitors is associated with the development of drug-specific hypertension via endothelial cell damage and endothelin-1 expression. Our findings are invaluable in establishing safer anticancer therapies and strategies to prevent the development of vascular toxicity in high-risk patients.
(徳島大学機関リポジトリ): ● Metadata: 2012024
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.biopha.2023.115504
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37722188; ● Search Scopus @ Elsevier (PMID): 37722188; ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2023.115504

(徳島大学機関リポジトリ: 2012024, DOI: 10.1016/j.biopha.2023.115504, PubMed: 37722188) Mami Neishi, Hirofumi Hamano, Takahiro Niimura, Masaya Denda, Kenta Yagi, Koji Miyata, Tsung-Jen Lin, Tsukasa Higashionna, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa and Hideki Nawa :
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases,
Toxicology and Applied Pharmacology, 475, 116632, 2023.

(要約): It is unclear whether the s (-) form of esomeprazole (EPZ) has an improved safety profile when compared with its racemic form omeprazole (OPZ). We assessed the potential complications of these optical isomers when combined with cilostazol, clopidogrel, and prasugrel, which are frequently used concomitant medications. Using two adverse event spontaneous reporting databases, Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS), adverse event names for hemorrhage, venous/arterial embolization, and thrombus were obtained from the Medical Dictionary for Regulatory Activities. Reported odds ratios were calculated using a 2 × 2 contingency table, and a signal was considered present if the lower limit of the 95% confidence interval was >1. In combination with cilostazol, a hemorrhagic signal for OPZ in JADER and arterial emboli and thrombus signals for EPZ were detected in both databases. In combination with clopidogrel, OPZ showed arterial emboli and thrombus signals in JADER and venous/arterial emboli and thrombus signals in FAERS, while EPZ displayed arterial emboli and thrombus signals in FAERS. In contrast, when in combination with prasugrel, there were no adverse event signals in either database. This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design.
(キーワード): Humans / United States / Esomeprazole / Omeprazole / Clopidogrel / Prasugrel Hydrochloride / Cilostazol / Adverse Drug Reaction Reporting Systems / Hemorrhage / Drug-Related Side Effects and Adverse Reactions / Databases, Factual
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.taap.2023.116632
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37482254; ● Summary page in Scopus @ Elsevier: 2-s2.0-85165980754

(DOI: 10.1016/j.taap.2023.116632, PubMed: 37482254, Elsevier: Scopus) Takahiro Niimura, Koji Miyata, Hirofumi Hamano, Yuuki Nounin, Hiroto Unten, Masaki Yoshino, Satoru Mitsuboshi, Fuka Aizawa, Kenta Yagi, Toshihiro Koyama, Mitsuhiro Goda, Yasunari Kanda, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa :
Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).,
Drug Safety, 2023.

(要約): Systematic evaluation of ALK inhibitor-associated adverse events revealed differences in the cardiotoxicity profiles among ALK inhibitors. Understanding the differences in the cardiovascular toxicity profile of each ALK inhibitor will contribute to safe drug therapy when switching between ALK inhibitors.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s40264-023-01300-9
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37106270; ● Search Scopus @ Elsevier (PMID): 37106270; ● Search Scopus @ Elsevier (DOI): 10.1007/s40264-023-01300-9

(DOI: 10.1007/s40264-023-01300-9, PubMed: 37106270) Kenta Yagi, Akinori Maruo, Shunsuke Ishida, Fuka Aizawa, Soichiro Ushio, Satoshi Sakaguchi, Makoto Kajizono, Takahiro Niimura, Mitsuhiro Goda, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa :
Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.,
Clinical and Experimental Medicine, 2023.

(要約): Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (N = 190) or vonoprazan (N = 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (p < 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s10238-023-01008-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36738305; ● Search Scopus @ Elsevier (PMID): 36738305; ● Search Scopus @ Elsevier (DOI): 10.1007/s10238-023-01008-1

(DOI: 10.1007/s10238-023-01008-1, PubMed: 36738305) Takahiro Niimura, Yoshito Zamami, Koji Miyata, Takahisa Mikami, Mizuho Asada, Keijo Fukushima, Masaki Yoshino, Satoru Mitsuboshi, Naoto Okada, Hirofumi Hamano, Takumi Sakurada, Rie Matsuoka-Ando, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Masayuki Chuma, Toshihiro Koyama, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Hiromichi Fujino, Yoshihiro Yamanishi and Keisuke Ishizawa :
Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.,
Journal of Clinical Pharmacology, 63, 4, 473-479, 2022.

(要約): Myasthenia gravis (MG) is a rare but fatal adverse event of immune checkpoint inhibitors (ICIs). We assessed whether patient characteristics differed between those with ICI-related myasthenia gravis and those with idiopathic myasthenia gravis. Reports from the US Food and Drug Administration Adverse Event Reporting System were analyzed. Multivariate analyses were conducted to evaluate the associations between age, sex, and ICI treatment and the reporting rate of myasthenia gravis. Among 5 464 099 cases between 2011 and 2019, 53 447 were treated with ICIs. Myasthenia gravis was reported more often in ICI users. Multiple logistic regression analyses showed that the reporting rate of ICI-related myasthenia gravis did not differ significantly between men and women; however, it was higher in older people than in younger people (adjusted odds ratio, 2.4 [95%CI, 1.84-3.13]). We also investigated useful signs for the early detection of myositis and myocarditis, which are fatal when overlapping with ICI-related myasthenia gravis. Patients with elevated serum creatine kinase or troponin levels were more likely to have concurrent myositis and myocarditis. Unlike idiopathic myasthenia gravis, there was no sex difference in the development of ICI-related myasthenia gravis, which may be more common in older people. Considering the physiological muscle weakness that occurs in the elderly, it may be necessary to monitor ICI-related myasthenia gravis more closely in older people.
(キーワード): Male / United States / Humans / Female / Aged / Immune Checkpoint Inhibitors / United States Food and Drug Administration / Myocarditis / Myasthenia Gravis / Myositis
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/jcph.2187
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36453166; ● Search Scopus @ Elsevier (PMID): 36453166; ● Search Scopus @ Elsevier (DOI): 10.1002/jcph.2187

(DOI: 10.1002/jcph.2187, PubMed: 36453166) Rie Ando-Matsuoka, Kenta Yagi, Mayu Takaoka, Yuko Sakajiri, Tomokazu Shibata, Ryusuke Sawada, Akinori Maruo, Koji Miyata, Fuka Aizawa, Hirofumi Hamano, Takahiro Niimura, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Satoshi Sakaguchi, Yoshito Zamami, Yoshihiro Yamanishi and Keisuke Ishizawa :
Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.,
Drug Development Research, 84, 1, 75-83, 2022.

(要約): Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion, used as first-line agents in treating peptic ulcers. However, we have previously reported that PPIs may diminish the therapeutic effect of anti-vascular endothelial growth factor (VEGF) drugs in patients with cancer. In this study, we explored the effects of vonoprazan, a novel gastric acid secretion inhibitor used for the treatment of peptic ulcers, on the secretion of VEGF in cancer cells and attempted to propose it as an alternative PPI for cancer chemotherapy. The effects of PPI and vonoprazan on VEGF expression in cancer cells were compared by real-time reverse transcription-polymerase chain reaction and ELISA. The interaction of vonoprazan and PPIs with transcriptional regulators by docking simulation analysis. In various cancer cell lines, including the human colorectal cancer cell line (LS174T), PPI increased VEGF messenger RNA expression and VEGF protein secretion, while this effect was not observed with vonoprazan. Molecular docking simulation analysis showed that vonoprazan had a lower binding affinity for estrogen receptor alpha (ER-α), one of the transcriptional regulators of VEGF, compared to PPI. Although the PPI-induced increase in VEGF expression was counteracted by pharmacological ER-α inhibition, the effect of vonoprazan on VEGF expression was unchanged. Vonoprazan does not affect VEGF expression in cancer cells, which suggests that vonoprazan might be an alternative to PPIs, with no interference with the therapeutic effects of anti-VEGF cancer chemotherapy.
(キーワード): Humans / Proton Pump Inhibitors / Endothelial Growth Factors / Molecular Docking Simulation / Peptic Ulcer / Pyrroles / Neoplasms
(徳島大学機関リポジトリ): ● Metadata: 2011046
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/ddr.22013
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36484282; ● Search Scopus @ Elsevier (PMID): 36484282; ● Search Scopus @ Elsevier (DOI): 10.1002/ddr.22013

(徳島大学機関リポジトリ: 2011046, DOI: 10.1002/ddr.22013, PubMed: 36484282) Masayuki Chuma, Hirofumi Hamano, Takashi Bando, Masateru Kondo, Naoto Okada, Yuki Izumi, Shunsuke Ishida, Toshihiko Yoshioka, Mizuho Asada, Takahiro Niimura, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Sachiko Kasamo, Yuki Izawa-Ishizawa, Momoyo Azuma, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa :
Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases.,
Basic & Clinical Pharmacology & Toxicology, 131, 6, 525-535, 2022.

(要約): There has been growing concern in worsening survival and renal outcomes following vancomycin-associated nephrotoxicity (VAN) onset, but the factors associated with these phenomena remain unclear. To examine these factors, we performed a retrospective study combining the analysis of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was used to evaluate the relationship between VAN and mortality using odds ratios (ORs) and 95% confidence intervals (CIs). Next, electronic medical records (EMRs) were examined in a more robust cohort for evaluation of the association between renal outcomes and worsening survival using Cox proportional hazards regression models. FAERS analysis revealed a significant correlation between VAN occurrence and increased mortality (OR: 1.30; 95% CI: 1.17-1.46). EMR analysis showed that non-recovery of VAN was associated with increased hospital mortality (hazard ratio [HR]: 4.05; 95% CI: 2.42-6.77) and 1-year mortality (HR: 3.03, 95% CI: 1.98-4.64). The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage 2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening survival outcomes were associated with non-recovery of VAN, whereby AKI stage 2 was a significant risk factor. Progression to severe VAN should be prevented for better survival outcomes.
(キーワード): Humans / Vancomycin / Retrospective Studies / Anti-Bacterial Agents / Acute Kidney Injury / Drug-Related Side Effects and Adverse Reactions / Risk Factors
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/bcpt.13799
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36169161; ● Search Scopus @ Elsevier (PMID): 36169161; ● Search Scopus @ Elsevier (DOI): 10.1111/bcpt.13799

(DOI: 10.1111/bcpt.13799, PubMed: 36169161) Hideki Nawa, Hirofumi Hamano, Takahiro Niimura, Koji Miyata, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa :
Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects.,
Clinical and Translational Science, 15, 12, 2982-2988, 2022.

(要約): Interstitial lung disease (ILD), as an adverse effect of certain drugs, leads to inflammation and damage in the walls of the alveoli, making it difficult for the alveoli to take up oxygen. Interstitial pneumonia with no identifiable cause is called idiopathic interstitial pneumonia (IIP), and, among the major IIPs, idiopathic pulmonary fibrosis (IPF) is diagnosed in about half of patients. Current treatment options are limited, among which the antifibrotic drugs nintedanib (Ofev) and pirfenidone (Pirespa) are the first-line drugs. In this study, we investigated the incidence of ILD possibly caused by antifibrotic agents using data from the Japanese Adverse Drug Event Report (JADER) database, a database of spontaneous adverse event reports published by the Pharmaceuticals and Medical Devices Agency (PMDA), and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), published by the FDA. We used the FAERS and JADER to detect the signals of adverse events on the basis of reporting odds ratios. The relationship between indications and adverse events was clarified by separating indications and adverse events using the spontaneous adverse event reporting database with novel drug involvement. Regarding the involvement of nintedanib and pirfenidone in the development of ILD, JADER and FAERS showed signals for both nintedanib and pirfenidone as suspect drugs, and no signals for nintedanib or pirfenidone as concomitant drug interactions were detected. We highlight this because there are only a few effective drugs for IPF, and effective and safe drug therapies should be implemented by taking into consideration drug-induced ILD.
(キーワード): United States / Humans / Pharmaceutical Preparations / Drug-Related Side Effects and Adverse Reactions / Lung Diseases, Interstitial / Databases, Factual / Pyridones / United States Food and Drug Administration / Idiopathic Pulmonary Fibrosis
(徳島大学機関リポジトリ): ● Metadata: 2010957
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cts.13419
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36128688; ● Search Scopus @ Elsevier (PMID): 36128688; ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13419

(徳島大学機関リポジトリ: 2010957, DOI: 10.1111/cts.13419, PubMed: 36128688) Shiori Nishiuchi, Kenta Yagi, Hiroumi Saito, Yoshito Zamami, Takahiro Niimura, Koji Miyata, Yoshika Sakamoto, Kimiko Fukunaga, Shunsuke Ishida, Hirofumi Hamano, Fuka Aizawa, Mitsuhiro Goda, Masayuki Chuma, Yuki Izawa-Ishizawa, Hideki Nawa, Hiroaki Yanagawa, Yasunari Kanda and Keisuke Ishizawa :
Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis.,
European Journal of Pharmacology, 928, 175083, 2022.

(要約): The Gene Expression Omnibus (GEO), Library of Integrated Network-based Cellular Signatures (LINCS), and Food and Drug Administration Adverse Events Reporting System (FAERS) databases were used to extract candidate prophylactic drugs. Mouse models of doxorubicin-induced cardiac events were generated by intraperitoneal administration of 20 mg/kg of doxorubicin on Day 1 and oral administration of prophylactic candidate drugs for 6 consecutive days beginning the day before doxorubicin administration. On Day 6, mouse hearts were extracted and examined for mRNA expression of apoptosis-related genes.
(キーワード): Animals / アポトーシス (apoptosis) / Cardiotoxicity / データ解析 (data analysis) / Doxorubicin / Mice / Myocytes, Cardiac / Pharmaceutical Preparations / RNA, Messenger / Sirolimus
(徳島大学機関リポジトリ): ● Metadata: 2010188
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.ejphar.2022.175083
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35659512; ● Search Scopus @ Elsevier (PMID): 35659512; ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2022.175083

(徳島大学機関リポジトリ: 2010188, DOI: 10.1016/j.ejphar.2022.175083, PubMed: 35659512) Masaya Kanda, Mitsuhiro Goda, Akiko Maegawa, Toshihiko Yoshioka, Ami Yoshida, Koji Miyata, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Takumi Sakurada, Masayuki Chuma, Kenta Yagi, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshito Zamami and Keisuke Ishizawa :
Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis.,
Clinical and Translational Science, 15, 7, 1664-1675, 2022.

(要約): Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin-induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin-induced renal injury, Library of Integrated Network-based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin-induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin-induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin-induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin-induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin-induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary.
(キーワード): Acute Kidney Injury / Animals / Cisplatin / データ解析 (data analysis) / Fenofibrate / 腎疾患 (kidney disease) / Mice / Prospective Studies
(徳島大学機関リポジトリ): ● Metadata: 2010189
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cts.13282
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35445533; ● Search Scopus @ Elsevier (PMID): 35445533; ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13282

(徳島大学機関リポジトリ: 2010189, DOI: 10.1111/cts.13282, PubMed: 35445533) Kenta Yagi, Yasutaka Sato, Satoshi Sakaguchi, Mitsuhiro Goda, Hirofumi Hamano, Fuka Aizawa, Mayuko Shimizu, Arisa Inoue-Hamano, Toshihide Nishimori, Masato Tagi, Marina Kanno, Rie Matsuoka-Ando, Toshihiko Yoshioka, Yoshiko Matstubara, Yuki Izawa-Ishizawa, Rieko Shimizu, Akinori Maruo, Yurika Kuniki, Yoshika Sakamoto, Sayuri Itobayashi, Yoshito Zamami, Hiroaki Yanagawa and Keisuke Ishizawa :
A web-based survey of educational opportunities of medical professionals based on changes in conference design during the COVID-19 pandemic.,
Education and Information Technologies, 27, 10371-10386, 2022.

(要約): The online version contains supplementary material available at 10.1007/s10639-022-11032-5.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s10639-022-11032-5
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35464114; ● Search Scopus @ Elsevier (PMID): 35464114; ● Search Scopus @ Elsevier (DOI): 10.1007/s10639-022-11032-5

(DOI: 10.1007/s10639-022-11032-5, PubMed: 35464114) Masayuki Chuma, Aki Nakamoto, Takashi Bando, Takahiro Niimura, Yutaka Kondo, Hirofumi Hamano, Naoto Okada, Mizuho Asada, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Toshihiko Yoshioka, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshikazu Tasaki and Keisuke Ishizawa :
Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis.,
Clinical Infectious Diseases, 75, 8, 1416-1422, 2022.

(要約): There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs. We used a mixed approach that combines two methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the FDA Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population. In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83, 95% confidence interval [CI]: 1.43-10.26) but not DAP-related myopathy (OR: 1.72, 95% CI: 0.95-3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69, 95% CI: 4.31-7.51) and rhabdomyolysis (ROR: 5.77, 95% CI: 4.33-7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis. The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety.
(徳島大学機関リポジトリ): ● Metadata: 2010607
(出版サイトへのリンク): ● Publication site (DOI): 10.1093/cid/ciac128
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35262686; ● Search Scopus @ Elsevier (PMID): 35262686; ● Search Scopus @ Elsevier (DOI): 10.1093/cid/ciac128

(徳島大学機関リポジトリ: 2010607, DOI: 10.1093/cid/ciac128, PubMed: 35262686) Yoshito Zamami, Takahiro Niimura, Takehiro Kawashiri, Mitsuhiro Goda, Yutaro Naito, Keijo Fukushima, Soichiro Ushio, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Koji Miyata, Kenshi Takechi, Masayuki Chuma, Toshihiro Koyama, Daisuke Kobayashi, Takao Shimazoe, Hiromichi Fujino, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data.,
Biomedicine & Pharmacotherapy, 148, 2022.

(要約): Thus, drug repositioning using data from large-scale basic and clinical databases enables the discovery of new indications for approved drugs with a high probability of success.
(キーワード): Animals / Anticholesteremic Agents / Antineoplastic Agents / Big Data / Databases, Factual / Drug Repositioning / Humans / Hyperalgesia / Japan / Male / Mice / Mice, Inbred BALB C / Oxaliplatin / Peripheral Nervous System Diseases / Pre-Exposure Prophylaxis / Rats / Rats, Sprague-Dawley / Retrospective Studies / Simvastatin
(徳島大学機関リポジトリ): ● Metadata: 2010230
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.biopha.2022.112744
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35240525; ● Search Scopus @ Elsevier (PMID): 35240525; ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2022.112744

(徳島大学機関リポジトリ: 2010230, DOI: 10.1016/j.biopha.2022.112744, PubMed: 35240525) Yasutaka Sato, Satoshi Sakaguchi, Kenshi Takechi, Masayuki Chuma, Kenta Yagi, Chikako Kane, Mitsuhiro Goda, Hirofumi Hamano, Yuki Aoe, Hiroshi Nokihara, Yoshiaki Kubo, Ichiro Hashimoto and Hiroaki Yanagawa :
Trends in Investigator-Initiated Clinical Studies at a University Hospital after Enforcement of the 2018 Clinical Trials Act in Japan.,
Biological & Pharmaceutical Bulletin, 45, 3, 374-377, 2022.

(要約): In April 2018, the Clinical Trials Act pertaining to investigator-initiated clinical trials was passed in Japan. The purpose of this study was to investigate activity in investigator-initiated clinical studies before and after enforcement of the new Clinical Trials Act. This was done by analysing the records of the Ethics Committee of Tokushima University Hospital, which reviews studies based on the Japanese government's Ethical Guidelines for Medical and Health Research Involving Human Subjects prior to the Clinical Trials Act, and records of the Certified Review Board established at Tokushima University under the Clinical Trials Act in 2018. The number of new applications to these two review boards during fiscal years 2015-2017 (pre-Act) and fiscal years 2018 and 2019 (post-Act) were used as an indicator of activity in investigator-initiated clinical studies. The number of new applications to the Ethics Committee was 303, 261, 316, 303, and 249 in 2015, 2016, 2017, 2018, and 2019, respectively. The data show that the total number of new interventional studies decreased from 50.3 in average in 2015-2017 (pre-Act) to 42 in 2018 and 40 in 2019 (post-Act), respectively. These results suggest that fewer interventional studies were started following enforcement of the new Clinical Trials Act. To confirm this trend and identify contributing factors, further studies are required. In addition, possible way, such as broader contribution of clinical research coordinators, to promote clinical studies in the new Clinical Trials Act era should be examined.
(キーワード): Clinical Trials as Topic / Hospitals, University / Humans / Japan
(徳島大学機関リポジトリ): ● Metadata: 2010187
(出版サイトへのリンク): ● Publication site (DOI): 10.1248/bpb.b21-00753
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35228403; ● CiNii @ 国立情報学研究所 (CRID): 1390854717424551552; ● Summary page in Scopus @ Elsevier: 2-s2.0-85125568858

(徳島大学機関リポジトリ: 2010187, DOI: 10.1248/bpb.b21-00753, PubMed: 35228403, CiNii: 1390854717424551552, Elsevier: Scopus) Naoto Okada, Yuki Izumi, Aki Nakamoto, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa :
Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study.,
Clinical Therapeutics, 43, 11, 1910-1920.e3, 2021.

(要約): The prevalences of VIN were 29.5% (18/61) and 7.1% (3/42) in the VT and VC groups, respectively. Multivariate logistic regression analysis of data from all patients revealed concurrent use of tazobactam/piperacillin (odds ratio [OR] = 4.59; P = 0.039) and AUC increase (OR = 1.01; P < 0.01) as risk factors for VIN, but only concurrent use of tazobactam/piperacillin was identified as a risk factor in patients with an AUC of <600 μg · h/mL, the guideline-recommended value (OR = 9.52; P = 0.041). Moreover, the vancomycin exposure-toxicity curve showed that in the guideline-recommended AUC range, VIN probability was consistently higher and the slope of VIN probability was greater in the VT group than in the VC group.
(キーワード): Acute Kidney Injury / Anti-Bacterial Agents / Bayes Theorem / Cefepime / Drug Therapy, Combination / Humans / Penicillanic Acid / Piperacillin / Piperacillin, Tazobactam Drug Combination / Prevalence / Retrospective Studies / Vancomycin
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.clinthera.2021.09.007
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34642081; ● Search Scopus @ Elsevier (PMID): 34642081; ● Search Scopus @ Elsevier (DOI): 10.1016/j.clinthera.2021.09.007

(DOI: 10.1016/j.clinthera.2021.09.007, PubMed: 34642081) Chikako Kane, Satoshi Sakaguchi, Masayuki Chuma, Kenta Yagi, Kenshi Takechi, Yuki Aoe, Tomoko Takagai and Hiroaki Yanagawa :
Research Ethics Consultation in Nursing Studies.,
Journal of Empirical Research on Human Research Ethics : JERHRE, 17, 1-2, 63-69, 2021.

(要約): = 12; 28%). Future studies should investigate international settings and address the relevance of research ethics consultation to promote proper nursing studies.
(キーワード): Ethics Consultation / Ethics, Research / Humans / Research Personnel / Retrospective Studies
(出版サイトへのリンク): ● Publication site (DOI): 10.1177/15562646211036577
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34374568; ● Search Scopus @ Elsevier (PMID): 34374568; ● Search Scopus @ Elsevier (DOI): 10.1177/15562646211036577

(DOI: 10.1177/15562646211036577, PubMed: 34374568) Hideki Nawa, Takahiro Niimura, Hirofumi Hamano, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa :
Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects.,
Frontiers in Pharmacology, 12, 655605, 2021.

(要約): From 2002 to 2018, the number of patients with prostate cancer significantly increased from 679,023 to 1276,106 worldwide. Total prostatectomy (including robot-assisted prostatectomy), radiation therapy, and pharmacological treatment are commonly used to treat prostate cancer. The Chief of the Pharmaceutical Safety Division, that is, the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ), recently called for the revision of package inserts for ethical drugs. However, the pathogenesis of interstitial lung disease (ILD), a serious drug-induced adverse effect, remains unclear. Moreover, there have been no large-scale evaluations of potential complications associated with currently used antiandrogens, which are commonly employed to treat prostate cancer. Hence, ILD, as an adverse event, remains poorly understood. Therefore, we conducted a survey of reports in the Japanese Adverse Drug Event Report (JADER) database to investigate the potential association between the reporting of ILD and antiandrogen drug use in clinical practice. The occurrence of ILD was investigated by evaluating the relationship between antiandrogen drug use and ILD. Adverse event signals were detected with reporting odds ratios (RORs), using data from the JADER and FDA Adverse Event Reporting System (FAERS) databases, for the analysis of post-marketing adverse event reports. The JADER was used to examine the time profile of adverse event occurrence for each drug, whereas the FAERS was used to screen cases of unknown adverse events and analyze their trends of occurrence. The analysis of data from both databases revealed the 95% confidence interval lower limits of ROR for bicalutamide and flutamide to be > 1, and adverse event signals were detected following the use of either drug. While caution should be exercised for drugs that are new to the market, we conclude that drugs with similar therapeutic effects that have been in use for a long period should also be re-examined for potential adverse events.
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fphar.2021.655605
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34177574; ● Search Scopus @ Elsevier (PMID): 34177574; ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2021.655605

(DOI: 10.3389/fphar.2021.655605, PubMed: 34177574) Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Yoichi Murai, Yoshito Zamami, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Masayuki Chuma, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Effects of 5-HT₃ receptor antagonists on cisplatin-induced kidney injury.,
Clinical and Translational Science, 2021.

(要約): receptor antagonists do not worsen cisplatin-induced acute kidney injury. The findings should be validated in a prospective controlled trial before implementation in clinical practice.
(徳島大学機関リポジトリ): ● Metadata: 2008943
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/cts.13045
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33982438; ● Search Scopus @ Elsevier (PMID): 33982438; ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13045

(徳島大学機関リポジトリ: 2008943, DOI: 10.1111/cts.13045, PubMed: 33982438) Hideki Nawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa :
Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.,
Cancer Reports, 2021.

(要約): We evaluated the relationship between the CDK4/6 inhibitors (abemaciclib and palbociclib) and interstitial lung disease in clinical practice using data from the Japanese Adverse Drug Event Report (JADER) database and FDA Adverse Event Reporting System (FAERS) to detect adverse event signals with reported odds ratios (RORs). Furthermore, we performed an adverse event-time analysis for each drug using data from the JADER database to examine the time of onset of the adverse events. The analysis of the reports in the JADER database showed that the lower limit of the 95% confidence interval (CI) of ROR for abemaciclib was >1 regardless of age, and a signal was detected. Interstitial lung disease associated with abemaciclib and palbociclib use has been reported, with an average onset period from treatment initiation [median (25th-75th quartile)] of 65.1 [56.0 days (25.3-98.3 days)] and 53.1 days [38.0 days (10.8-76.0 days)], respectively. The analysis of the reports in the FAERS showed that the lower limit of the 95% CI of the ROR for the two drugs was >1, and a signal was detected.
(徳島大学機関リポジトリ): ● Metadata: 2009208
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/cnr2.1402
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33939324; ● Search Scopus @ Elsevier (PMID): 33939324; ● Search Scopus @ Elsevier (DOI): 10.1002/cnr2.1402

(徳島大学機関リポジトリ: 2009208, DOI: 10.1002/cnr2.1402, PubMed: 33939324) 石澤有紀, 合田光寛, 相澤風花, 座間味義人, 濱野裕章, 八木健太, 池田康将, 石澤啓介, 玉置俊晃 :
薬剤誘発性大動脈解離易発症モデルマウスを用いた薬効評価,
四国医学雑誌, 77, 1,2, 57-62, 2021年.

(要約): Aortic dissection (or dissecting aortic aneurysm) is a condition in which the aortic wall is separated into two layers at the medial level to form a pseudocavity. The intima crack, called the ``entry'', allows blood to tear through the medial layer and flow in. The location of the ``entry'' and the extent of the dissection can cause a variety of serious complications, including rupture, cardiac tamponade, and obstruction of branched vessels. According to the Guideline on Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection 2020, it is estimated that 61.4% of the onset of dissection die before arrival at the hospital, and 93% will die within 24 hours after the onset. It has been suggested that the morbidity rate has been increasing in recent years. Since many of them have a fatal prognosis, it is an important issue to prevent the onset itself. However, no effective therapeutic agent or preventive strategy has been established so far. The first reason is that it is extremely difficult to design clinical studies because aortic dissection traced the rapid onset and progression. The second is that the pathophysiology and preventive drug search are not sufficiently conducted even at the basic research level. Epidemiologically, the results of the International Registry of Aortic Dissection (IRAD) revealed that aging, hypertension, atherosclerosis, and hereditary connective tissue diseases are risk factors. The aortic aneurysm also shows similar pathological conditions caused by these risk factors. However, one of the major differences between aneurysm and dissection is the presence of aortic intima rupture. Therefore, we attempted to establish a mouse model developing dissection at a high rate by adding the endothelial dysfunction to a pharmacologically induced aortic aneurysm model mouse. Furthermore, we evaluated the efficacy of pitavastatin and several nutrients using our novel model mice and verified its usefulness as a model animal.
(キーワード): aortic dissection / endothelial dysfunction / statin / ポリフェノール (polyphenol) / large medical databases
(徳島大学機関リポジトリ): ● Metadata: 2008973
(文献検索サイトへのリンク): ● CiNii @ 国立情報学研究所 (CRID): 1050585658873174784

(徳島大学機関リポジトリ: 2008973, CiNii: 1050585658873174784) Masayuki Chuma, Kenshi Takechi, Kenta Yagi, Satoshi Sakaguchi, Hiroshi Nokihara, Chikako Kane, Yasutaka Sato, Takahiro Niimura, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa and Hiroaki Yanagawa :
Academic investigators' interest in promoting specified clinical trials : Questionnaire survey before and after implementation of the Clinical Trial Act,
The Journal of Medical Investigation : JMI, 68, 1.2, 71-75, 2021.

(要約): Background : Enforcement of the 2018 Clinical Trials Act (CTA) in Japan resulted in strict and complicated regulations surrounding intervention studies. Few Japan-specific measures have been developed to promote intervention studies in Japan despite concerns about CTA's negative influence on such studies. Therefore, this study examined the changes in academic investigators' interest in conducting clinical studies before and after enforcement of the CTA to determine measures to promote specified clinical trials. Methods : We conducted a questionnaire survey with investigators belonging to the Institute of Biomedical Sciences, Tokushima University Graduate School, before and after enforcement of the CTA. Results : Investigators had lesser interest in intervention studies in the post-questionnaire survey (post) group than in the pre-questionnaire survey (pre) group. Their desire for "project management" was significantly higher in the post-group than in the pre-group. Their desire for "support for preparing documents when conducting specified clinical trials" was significantly higher in the group interested in conducting specified clinical trials than that in the not-interested group. Conclusion : We revealed that investigators were highly interested in "project management" and "support for preparing documents when conducting specified clinical trials" after enforcement of the CTA. Measures for these desires may promote specified clinical trials. J. Med. Invest. 68 : 71-75, February, 2021.
(徳島大学機関リポジトリ): ● Metadata: 2008922
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.68.71
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994483; ● Search Scopus @ Elsevier (PMID): 33994483; ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.71

(徳島大学機関リポジトリ: 2008922, DOI: 10.2152/jmi.68.71, PubMed: 33994483) Kenta Yagi, Marin Mitstui, Yoshito Zamami, Takahiro Niimura, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Masayuki Chuma, Kimiko Fukunaga, Takahiro Shibata, Shunsuke Ishida, Takumi Sakurada, Naoto Okada, Hirofumi Hamano, Yuya Horinouchi, Yasumasa Ikeda, Hiroaki Yanagawa and Keisuke Ishizawa :
Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.,
Cancer Medicine, 2020.

(要約): PPIs prevent hypertension in bevacizumab-treated patients but may reduce bevacizumab's anti-tumoral effects by inducing VEGF expression.
(徳島大学機関リポジトリ): ● Metadata: 2009207
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/cam4.3587
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33231381; ● Search Scopus @ Elsevier (PMID): 33231381; ● Search Scopus @ Elsevier (DOI): 10.1002/cam4.3587

(徳島大学機関リポジトリ: 2009207, DOI: 10.1002/cam4.3587, PubMed: 33231381) Kondo Masateru, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Hosooka Mayuko, Kagimoto Yuu, Saito Naoko, Matsuoka Rie, Yoshito Zamami, Masayuki Chuma, Kenta Yagi, Kenshi Takechi, Koichi Tsuneyama and Keisuke Ishizawa :
Preventive Effects of Quercetin against the Onset of Atherosclerosis-Related Acute Aortic Syndromes in Mice,
International Journal of Molecular Sciences, 21, 19, 2020.

(徳島大学機関リポジトリ): ● Metadata: 2008266
(出版サイトへのリンク): ● Publication site (DOI): 10.3390/ijms21197226
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-85091999803

(徳島大学機関リポジトリ: 2008266, DOI: 10.3390/ijms21197226, Elsevier: Scopus) 加根千賀子, 武智研志, 中馬真幸, 八木健太, 高開登茂子, 楊河宏章 :
クリニカルリサーチナースの在り方とその教育方法に関する研究,
薬理と治療, 48, Suppl.2, s164-s169, 2020年.

MISC

研究者総覧に該当データはありませんでした。

総説・解説

Yoshito Zamami, Hirofumi Hamano, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Drug-Repositioning Approaches Based on Medical and Life Science Databases.,
Frontiers in Pharmacology, 12, 752174, Nov. 2021.

(徳島大学機関リポジトリ): ● Metadata: 2009778
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fphar.2021.752174
(文献検索サイトへのリンク): ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2021.752174

(徳島大学機関リポジトリ: 2009778, DOI: 10.3389/fphar.2021.752174)

講演・発表

Iida Midori, Yamanishi Yoshihiro, Kuniki Yurika, Kenta Yagi, Mitsuhiro Goda, Namba Satoko, Takeshita Jun-ichi, Sawada Ryusuke, Iwata Michio, Yoshito Zamami and Keisuke Ishizawa :
A Computational Method for Predicting Synergistic Drug Combinations Using Network Propagation and Trans-OmicsAnalysis,
1st Asia&Pacific Bioinformatics Joint Conference JSBi, GIW, InCoB, APBC, and ISCB-Asia, Okinawa, Oct. 2024. Kenta Yagi, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Exploration of drugs that affect treatment with anti-VEGF drugs,
30th Congress of the Federation of Asian Pharmaceutical Associations; FAPA2024, Seoul, Oct. 2024. Kanda Masaya, Mitsuhiro Goda, Kei Kawada, Bando Takashi, Ishida Shunsuke, Itokazu Shuto, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Development of a strategy to prevent cisplatin-induced kidney injury by targeting MATE-type transporters,
ISSX/JSSX 2024 Meeting, ホノルル, Sep. 2024. Mitsuhiro Goda, Kanda Masaya, Kei Kawada, Ogawa Atsushi, Hyodo Mizusa, Kenta Yagi, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
MATE are bound to a multiprotein complex containing NHE3, and it's causing functional interactions,
ISSX/JSSX 2024 Meeting, Sep. 2024. Takahiro Niimura, Koji Miyata, Kenta Yagi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
Evaluation of cardiovascular toxicity profile of ALK inhibitors using adverse event reporting database.,
ASCPT 2024 Annual Meeting Colorado Springs March 2024, Colorado Springs, Mar. 2024. Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondo, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa :
Fluoroquinolones attribute aortic diseases through endothelial dysfunction.,
ASCPT 2024 Annual Meeting, Colorado Springs, Mar. 2024. Fuka Aizawa, okabayashi Ami, moriyama daishi, Kenta Yagi, takahashi shimon, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa :
HMG-CoA reductase inhibitor ameliorate platinum and taxane induced peripheral neuropathy: basic and medical database analysis,
81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023. Kenta Yagi, Fuka Aizawa, Takahiro Niimura, Maruo Akinori, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa :
Impact of Supportive Care Drugs on Treatment Effectiveness in Cancer Chemotherapy,
81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023. Kei Kawada, Ishida Tomoaki, Morisawa Shumpei, Jobu Kohei, Higasi Youichirou, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa :
Atractylodes lancea Rhizome-derived Exosome-like Nanoparticles Suppress Lipopolysaccharide-induced Inflammation in Murine Microglial Cells,
81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023. Mitsuhiro Goda, Kanda Masaya, Yoshioka Toshihiko, Miyata Koji, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Sakurada Takumi and Yuki Izawa-Ishizawa :
Discovery of preventive drugs for cisplatin-induced acute kidney injury.,
19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023. Miyata Koji, Yuki Izawa-Ishizawa, Takahiro Niimura, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa :
Investigation of PDE5 Inhibitors and Artery Diseases Using Real-World Database,
19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023. 糸数柊人, 石澤有紀, 宮田辰巳, 福岡媛乃, 兵藤瑞紗, 山尾珠美, 相澤風花, 新村貴博, 八木健太, 川田敬, 合田光寛, 石澤啓介 :
血管内皮細胞内ERK5が大動脈疾患発症に及ぼす影響の検討,
第63 回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2024年11月. 石田朋奈, 合田光寛, 神田将哉, 加納菜々, 吉岡俊彦, 川田敬, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
MATE型輸送体を標的とするシスプラチン誘発腎障害予防薬の開発,
第63 回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2024年11月. 高岡麻佑, 八木健太, 合田光寛, 相澤風花, 新村貴博, 川田敬, 石澤有紀, 石澤啓介 :
造血幹細胞移植前処置薬の薬効を増強させる併用薬剤の作用メカニズムの解明,
第63 回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2024年11月. 川田敬, 山本高成, 佐藤智恵美, 小川敦, 相澤風花, 八木健太, 石澤有紀, 新村貴博, 阿部真治, 合田光寛, 石澤啓介 :
国立大学での学部教育の実情と学生のキャリアアップ支援,
第34回日本医療薬学年会, 2024年11月. 神田将哉, 合田光寛, 石田朋奈, 石田俊介, 櫻田巧, 坂東貴司, 川田敬, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 桐野靖, 石澤啓介 :
シスプラチン誘発腎障害予防薬としてのSGLT2阻害薬の作用機序解明,
第34回日本医療薬学年会, 2024年11月. 河野祐輝, 新村貴博, 佐藤智恵美, 合田光寛, 川田敬, 八木健太, 相澤風花, 石澤有紀, 石澤啓介 :
小児抗菌薬適正使用加算が抗菌薬処方動向に与える影響の検討,
第34回日本医療薬学年会, 2024年11月. 竹内大平, 吉岡俊彦, 八木健太, 馬場彩花, 竹原恵美, 藤本啓介, 住友弘幸, 坂本晋一, 宮本直輝, 森下敦司, 河北直也, 鳥羽博明, 石澤啓介, 滝沢宏光 :
JCOG0802/WJOG4607Lの結果を踏まえた肺癌術後他疾患罹患のリアルワールドデータ検証,
第77回日本胸部外科学会定期学術集会, 2024年11月. 石田朋奈, 合田光寛, 神田将哉, 加納菜々, 吉岡俊彦, 川田敬, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
シスプラチン誘発腎障害に対するSGLT2阻害薬の有効性の検証,
次世代を担う若手のための創薬・医療薬理シンポジウム2024, 2024年9月. 髙岡麻佑, 八木健太, 合田光寛, 相澤風花, 新村貴博, 川田敬, 石澤有紀, 石澤啓介 :
造血幹細胞移植治療成績向上を目指した移植前処置薬の作用増強薬の探索,
次世代を担う若手のための創薬・医療薬理シンポジウム2024, 2024年9月. 神田将哉, 合田光寛, 石田朋奈, 石田俊介, 櫻田巧, 坂東貴司, 川田敬, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
シスプラチン誘発腎臓障害の原因にアプローチする新たな予防戦略の開発,
第145回日本薬理学会近畿部会, 2024年7月. 川田敬, 石田智滉, 福田仁, 久保亨, 濵田知幸, 相澤風花, 八木健太, 石澤有紀, 新村貴博, 阿部真治, 合田光寛, 北岡裕章, 石澤啓介 :
高齢心不全患者における長期入院の危険因子の検討,
第8回日本臨床薬理学会中国・四国地方会, 2024年7月. 八木健太, 今若清香, 髙岡麻佑, 岡本尚大, 相澤風花, 新村貴博, 合田光寛, 川田敬, 石澤有紀, 石澤啓介 :
Bcr-Abl 阻害剤に対する慢性骨髄性白血病細胞の耐性獲得メカニズムの探索,
第144回日本薬理学会近畿部会, 2024年3月. 石澤有紀, 宮田晃志, 辻中海斗, 糸数柊人, 宮田辰巳, 近藤正輝, 新村貴博, 吉岡俊彦, 相澤風花, 八木健太, 川田敬, 合田光寛, 石澤啓介 :
フルオロキノロン系抗菌薬による大動脈疾患リスクに関する2つの矛盾,
第144回日本薬理学会近畿部会, 2024年3月. 相澤風花, 岡林亜美, 森山大嗣, 八木健太, 新村貴博, 合田光寛, 石澤有紀, 川田敬, 石澤啓介 :
HMG-CoA還元酵素阻害剤はGST を介して抗がん剤誘発性機械的刺激応答閾値低下を改善する,
第144回日本薬理学会近畿部会, 2024年3月. 宮田辰巳, 石澤有紀, 宮田晃志, 糸数柊人, 辻中海斗, 福岡媛乃, 相澤風花, 新村貴博, 八木健太, 川田敬, 合田光寛, 石澤啓介 :
レボフロキサシンの血管炎症への影響,
第268回徳島医学会, 2024年3月. 糸数柊人, 石澤有紀, 宮田晃志, 宮田辰巳, 近藤正輝, 相澤風花, 新村貴博, 八木健太, 川田敬, 合田光寛, 石澤啓介 :
杜仲葉エキスによる大動脈疾患発症抑制効果の検討,
第268回徳島医学会, 2024年3月. 宮田晃志, 石澤有紀, 西穂香, 糸数柊人, 宮田辰巳, 辻中海斗, 近藤正輝, 新村貴博, 相澤風花, 八木健太, 川田敬, 合田光寛, 石澤啓介 :
フルオロキノロン系抗菌薬に関連した大動脈瘤解離には内皮障害が関与する,
第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, 2023年12月. 川田敬, 石田智滉, 福田仁, 兵頭勇己, 浜田知幸, 久保亨, 相澤風花, 八木健太, 石澤有紀, 新村貴博, 合田光寛, 石澤啓介 :
機械学習解析を用いた心不全治療薬の年齢別有効性の検討―高知急性非代償性心不全レジストリ研究より―,
第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, 2023年12月. 杉本祐悟, 合田光寛, 石田朋奈, 加納菜々, 神田将哉, 吉岡俊彦, 相澤風花, 新村貴博, 八木健太, 川田敬, 石澤有紀, 石澤啓介 :
SGLT2阻害薬によるシスプラチン誘発腎障害の抑制効果,
第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2023年10月. 八木健太, 新村貴博, 坂口暁, 相澤風花, 川田敬, 合田光寛, 石澤有紀, 石澤啓介 :
リアルワールドデータの医療への活用に向けて,
第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2023年10月. 川田敬, 石田智滉, 相澤風花, 八木健太, 石澤有紀, 新村貴博, 阿部真治, 合田光寛, 石澤啓介 :
植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 吉岡俊彦, 合田光寛, 石田朋奈, 杉本祐悟, 神田将哉, 櫻田巧, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 杉本祐悟, 合田光寛, 石田朋奈, 加納菜々, 神田将哉, 吉岡俊彦, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
慢性骨髄性白血病の薬剤耐性に有用な薬剤の探索,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 友近七海, 相澤風花, 薗田悠平, 西橋彩香, 宮内奏穂, 合田光寛, 八木健太, 新村貴博, 石澤有紀, 朝田瑞穂, 植沢芳広, 石澤啓介 :
実験的多発性硬化症モデルマウスに対するウルソデオキシコール酸の治療効果の検討,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 西穂香, 相澤風花, 石澤有紀, 辻中海斗, 宮田晃志, 吉岡俊彦, 近藤正輝, 糸数柊人, 宮田辰巳, 新村貴博, 相澤風花, 八木健太, 座間味義人, 合田光寛, 石澤啓介 :
血管新生阻害剤による大動脈解離発症のリスク因子解明,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 森山大嗣, 相澤風花, 岡林亜美, 合田光寛, 八木健太, 新村貴博, 石澤有紀, 石澤啓介 :
抗がん剤誘発性末梢神経障害に対するスタチン系薬剤の有効性ならびに作用標的の検討,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 内田和志, 運天拡人, 濱野裕章, 新村貴博, 合田光寛, 八木健太, 相澤風花, 石澤有紀, 座間味義人, 石澤啓介 :
免疫チェックポイント阻害剤関連心筋炎モデルマウスの作製とモデルマウスを用いた予防薬探索,
次世代を担う若手のための創薬・医療薬理シンポジウム2023, 2023年8月. 新村貴博, 宮田晃志, 八木健太, 相澤風花, 濱野裕章, 石澤有紀, 合田光寛, 座間味義人, 石澤啓介 :
有害事象報告データベースを活用したALK阻害薬の心血管毒性プロファイル解明,
生体機能と創薬シンポジウム2023, 2023年8月. 吉岡俊彦, 合田光寛, 杉本祐悟, 石田朋奈, 神田将哉, 櫻田巧, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果,
生体機能と創薬シンポジウム2023, 2023年8月. 坂東寛, 合田光寛, 新村貴博, 新田侑生, 中馬真幸, 北川航平, 相澤風花, 八木健太, 石澤有紀, 櫻田巧, 石澤啓介 :
大規模医療情報データベース解析を基盤としたラモトリギンの皮膚障害発現リスクに影響する薬剤の探索,
生体機能と創薬シンポジウム2023, 2023年8月. 吉岡俊彦, 合田光寛, 神田将哉, 杉本祐悟, 石澤有紀, 八木健太, 相澤風花, 宮田晃志, 新村貴博, 櫻田巧, 桐野靖, 石澤啓介 :
バルプロ酸ナトリウムのシスプラチン誘発腎障害予防薬としての可能性,
第267回徳島医学会学術集会, 2023年8月. 神田将哉, 合田光寛, 吉岡俊彦, 杉本祐悟, 櫻田巧, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
MATE型輸送体を標的とするシスプラチン誘発腎障害予防戦略の開発,
第32回霧島神経薬理フォーラム, 2023年8月. 相澤風花, 岡林亜美, 森山大嗣, 八木健太, 合田光寛, 新村貴博, 石澤有紀, 石澤啓介 :
抗がん剤誘発性末梢神経障害に対するHMG-CoA還元酵素阻害剤の多面的作用,
第2回あべの薬理学懇話会, 2023年8月. 相澤風花, 岡林亜美, 森山大嗣, 八木健太, 高橋志門, 新村貴博, 合田光寛, 石澤有紀, 石澤啓介 :
スタチンはOxaliplatin および Paclitaxel 誘発性末梢神経障害を改善する,
医療薬学フォーラム2023 / 第31回クリニカルファーマシーシンポジウム, 2023年7月. 川田敬, 石田智滉, 常風興平, 森沢惇平, 相澤風花, 八木健太, 石澤有紀, 新村貴博, 阿部真治, 合田光寛, 石澤啓介 :
植物由来Exosome-like Nanoparticles (ELNs)の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-,
第143回日本薬理学会近畿部会, 2023年6月. 岡本尚大, 八木健太, 今若清香, 髙岡麻佑, 國木悠理香, 石澤有紀, 相澤風花, 新村貴博, 合田光寛, 石澤啓介 :
慢性骨髄性白血病に対する新規分子標的治療薬の耐性メカニズムの探索,
第143回日本薬理学会近畿部会, 2023年6月. 阪本淑華, 友近七海, 新村貴博, 合田光寛, 相澤風花, 八木健太, 濱野裕章, 石澤有紀, 座間味義人, 石澤啓介 :
スニチニブ誘発心毒性に対する新規予防薬の探索と作用機序の検討,
日本医療薬学会第6回フレッシャーズ・カンファランス, 2023年6月. 運天拡人, 内田和志, 濱野裕章, 新村貴博, 合田光寛, 八木健太, 相澤風花, 石澤有紀, 座間味義人, 石澤啓介 :
免疫チェックポイント阻害剤関連心筋炎モデルマウスの確立と病理組織像の評価,
日本医療薬学会第6回フレッシャーズ・カンファランス, 2023年6月. 八木健太, 髙岡麻佑, 吉武愛哉, 丸尾陽成, 安藤里英, 相澤風花, 新村貴博, 石澤有紀, 濱野裕章, 合田光寛, 座間味義人, 石澤啓介 :
プロトンポンプ阻害剤およびボノプラザンがVEGF発現に与える影響,
日本薬学会第143年会, 2023年3月. 相澤風花, 岡林亜美, 森山大嗣, 八木健太, 合田光寛, 新田綾香, 新村貴博, 石澤有紀, 石澤啓介 :
抗がん剤誘発性末梢神経障害克服に向けたスタチン系薬剤による有効性検討,
日本薬学会第143年会, 2023年3月. 合田光寛, 糸林小友理, 神田将哉, 吉岡俊彦, 杉本祐悟, 石田朋奈, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 櫻田巧, 桐野靖, 石澤啓介 :
バルプロ酸ナトリウムのシスプラチン誘発腎障害に対する予防効果の作用機序解明,
日本薬学会第143年会, 2023年3月. 新村貴博, 運天拡人, 濱野裕章, 内田和志, 友近七海, 宮田晃志, 合田光寛, 八木健太, 相澤風花, 石澤有紀, 座間味義人, 石澤啓介 :
遺伝子改変マウスを用いた免疫チェックポイント阻害剤関連心筋炎の病態モデル開発,
日本薬学会第143年会, 2023年3月. 宮田晃志, 石澤有紀, 濱野裕章, 新村貴博, 相澤風花, 八木健太, 座間味義人, 合田光寛, 石澤啓介 :
ホスホジエステラーゼ5阻害剤に関連した動脈疾患,
日本薬学会第143年会, 2023年3月. 相澤風花, 八木健太, 新村貴博, 合田光寛, 座間味義人, 石澤有紀, 石澤啓介 :
データサイエンス×基礎によるCIPN支持療法薬の創出,
日本薬学会第143年会, 2023年1月. 新村貴博, 運天拡人, 濱野裕章, 内田和志, 宮田晃志, 合田光寛, 八木健太, 相澤風花, 石澤有紀, 座間味義人, 石澤啓介 :
PD-1ノックアウトマウスを用いた免疫チェックポイント阻害剤関連心筋炎の新規病態モデル開発,
第32回日本循環薬理学会, 2023年1月. 坂口暁, 佐藤康敬, 石田光代, 前田和輝, 二見明香里, 八木健太, 沖良祐, 藤田浩司, 楊河宏章, 和泉唯信, 梶龍兒, 石澤啓介 :
高用量メチルコバラミンの筋萎縮性側索硬化症に対する第III相試験の被験者及び家族におけるアンケート調査,
第43回日本臨床薬理学会学術総会, 2022年11月. 合田光寛, 神田将哉, 吉岡俊彦, 相澤風花, 櫻田巧, 小川敦, 新村貴博, 八木健太, 石澤有紀, 石澤啓介 :
がん薬物療法に伴う腎障害とその予防,
第96回日本薬理学会年会/第43回日本臨床薬理学学術総会シンポジウム6, 2022年11月. 合田光寛, 相澤風花, 八木健太, 新村貴博, 櫻田巧, 小川敦, 石澤有紀, 座間味義人, 石澤啓介 :
医療ビッグデータ解析と基礎研究を融合した研究手法によるハイブリッド創薬,
第96回日本薬理学会年会/第43回日本臨床薬理学学術総会日本臨床薬理学会共催シンポジウム(シンポジウム41), 2022年11月. 岡田直人, 中村信元, 清水太郎, 安藤英紀, 相澤風花, 新村貴博, 八木健太, 合田光寛, 石田竜弘, 石澤啓介 :
免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に関連する因子の検討,
第32回日本医療薬学学会, 2022年9月. 岡田直人, 中村信元, 清水太郎, 安藤英紀, 相澤風花, 新村貴博, 八木健太, 合田光寛, 石田竜弘, 石澤啓介 :
免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に影響を与える因子の検討,
第32回日本医療薬学会年会, 2022年9月. 八木健太, 丸尾陽成, 石田俊介, 鍛治園誠, 相澤風花, 宮田晃志, 新村貴博, 石澤有紀, 濱野裕章, 合田光寛, 座間味義人, 石澤啓介 :
ベバシズマブ治療継続にプロトンポンプ阻害剤，ボノプラザンが与える影響,
第32回日本医療薬学会年会, 2022年9月. 山川裕介, 八木健太, 吉岡俊彦, 佐藤真希, 丸尾陽成, 宮田晃志, 相澤風花, 國木悠理香, 新村貴博, 坂口暁, 石澤有紀, 合田光寛, 座間味義人, 石澤啓介 :
慢性骨髄性白血病患者における Bcr-Abl 阻害剤治療期間とアルコール摂取の関連,
第32回日本医療薬学会年会, 2022年9月. 合田光寛, 神田将哉, 吉岡俊彦, 新村貴博, 櫻田巧, 小川敦, 相澤風花, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
薬物療法の最適化を目指すリアルワールドデータ駆動型臨床薬理学研究,
第32回日本医療薬学会年会シンポジウム32, 2022年9月. 相澤風花, 岡林亜美, 森山大嗣, 薗田悠平, 高橋志門, 新村貴博, 合田光寛, 座間味義人, 吉岡俊彦, 八木健太, 石澤有紀, 石澤啓介 :
臨床薬理の視点で実践する創薬研究:抗がん剤有害事象をターゲットとしたトランスレーショナルリサーチ,
第32回日本医療薬学会年会シンポジウム55, 2022年9月. 相澤風花, 岡林亜美, 森山大嗣, 薗田悠平, 高橋志門, 新田綾香, 合田光寛, 八木健太, 新村貴博, 座間味義人, 石澤有紀, 石澤啓介 :
スタチンの pleiotropic effects: 抗がん剤誘発性末梢神経障害抑制作用の検討,
次世代を担う若手のための創薬・医療薬理シンポジウム2022, 2022年8月. 神田将哉, 合田光寛, 吉岡俊彦, 小川敦, 石田俊介, 新村貴博, 相澤風花, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
医療ビッグデータ解析を基盤としたシスプラチン誘発腎障害予防薬の探索,
次世代を担う若手のための創薬・医療薬理シンポジウム2022, 2022年8月. 宮田晃志, 石澤有紀, 辻中海斗, 大峯航平, 西穂香, 糸数柊人, 新村貴博, 近藤正輝, 相澤風花, 濱野裕章, 八木健太, 座間味義人, 合田光寛, 石澤啓介 :
フルオロキノロン系抗菌薬に関連した動脈瘤・解離の病態解明,
次世代を担う若手のための創薬・医療薬理シンポジウム2022, 2022年8月. 糸林小友理, 合田光寛, 杉本祐悟, 石田朋奈, 神田将哉, 吉岡俊彦, 小川敦, 櫻田巧, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの予防効果,
次世代を担う若手のための創薬・医療薬理シンポジウム2022, 2022年8月. 國木悠理香, 八木健太, 髙岡麻佑, 岡本尚大, 濱野裕章, 相澤風花, 新村貴博, 合田光寛, 石澤有紀, 座間味義人, 石澤啓介 :
慢性骨髄性白血病に対する既存承認薬とALDH阻害剤併用の有効性,
次世代を担う若手のための創薬・医療薬理シンポジウム2022, 2022年8月. 吉岡俊彦, 合田光寛, 糸林小友理, 杉本祐悟, 石田朋奈, 神田将哉, 小川敦, 櫻田巧, 相澤風花, 新村貴博, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
薬剤性腎障害予防を志向したドラッグリポジショニング研究,
第31回霧島神経薬理フォーラム, 2022年8月. 宮田晃志, 石澤有紀, 辻中海斗, 大峯航平, 西穂香, 糸数柊人, 新村貴博, 近藤正輝, 相澤風花, 濱野裕章, 八木健太, 座間味義人, 合田光寛, 石澤啓介 :
関連した動脈瘤・動脈解離:医療ビッグデータ解析と基礎薬理学実験によるアプローチ,
第29回市大フォーラム, 2022年8月. 合田光寛, 神田将哉, 吉岡俊彦, 吉田愛美, 糸林小友理, 新村貴博, 櫻田巧, 小川敦, 岡田直人, 相澤風花, 八木健太, 濱野裕章, 石澤有紀, 座間味義人, 石澤啓介 :
遺伝子発現および大規模医療情報データベースを活用したシスプラチン関連腎障害に対する予防薬の探索,
第51回日本心脈管作動物質学会学術集会, 2022年7月. 糸林小友理, 合田光寛, 吉田愛美, 杉本祐悟, 神田将哉, 吉岡俊彦, 櫻田巧, 相澤風花, 濱野裕章, 岡田直人, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
抗がん剤誘発急性腎障害に対するバルプロ酸ナトリウムの影響,
医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, 2022年7月. 八木健太, 高岡麻佑, 丸尾陽成, 相澤風花, 新村貴博, 石澤有紀, 濱野裕章, 合田光寛, 座間味義人, 石澤啓介 :
プロトンポンプ阻害剤，ボノプラザンが抗VEGF療法に与える影響,
医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, 2022年7月. 阪本淑華, 友近七海, 新村貴博, 合田光寛, 相澤風花, 八木健太, 西内栞, 生田賢治, 濱野裕章, 石澤有紀, 座間味義人, 石澤啓介 :
医療ビッグデータを活用したスニチニブ誘発心毒性に対する予防薬の探索,
医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, 2022年7月. 大峯航平, 近藤正輝, 合田光寛, 西穂香, 宮田晃志, 辻中海斗, 濱野裕章, 相澤風花, 八木健太, 座間味義人, 石澤啓介, 石澤有紀 :
大動脈瘤，解離に対する杜仲葉エキスの抑制効果の検討,
医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, 2022年7月. 國木悠理香, 八木健太, 高岡麻佑, 岡本尚大, 濱野裕章, 合田光寛, 新村貴博, 相澤風花, 石澤有紀, 座間味義人, 石澤啓介 :
慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果増強の検討,
医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, 2022年7月. 運天拡人, 濱野裕章, 新村貴博, 友近七海, 西内栞, 合田光寛, 八木健太, 相澤風花, 座間味義人, 石澤啓介 :
大規模医療情報データベースを用いたドキソルビシン誘発性心筋症に対する予防薬の開発,
医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウムシンポジウム 2, 2022年7月. 宮田晃志, 石澤有紀, 近藤正輝, 辻中海斗, 大峯航平, 西穂香, 糸数柊人, 新村貴博, 相澤風花, 濱野裕章, 八木健太, 座間味義人, 合田光寛, 石澤啓介 :
フルオロキノロン系抗菌薬による血管毒性の病態解明,
第141回日本薬理学会近畿部会, 2022年7月. 運天拡人, 濱野裕章, 新村貴博, 内田和志, 友近七海, 宮田晃志, 石田俊介, 合田光寛, 八木健太, 相澤風花, 座間味義人, 石澤啓介 :
免疫チェックポイント阻害剤関連心筋炎の解析に適した実験的病態モデルの開発,
第141回日本薬理学会近畿部会, 2022年7月. 土師正太郎, 藤田浩司, 沖良祐, 大崎裕亮, 金澤裕樹, 松元友暉, 有澤亜津子, 川井恒, 佐藤康敬, 八木健太, 坂口暁, 楊河宏章, 濱谷辰斗, 長野清一, 望月秀樹, 熱田直樹, 道勇学, 祖父江元, 原田雅史, 和泉唯信 :
EPI-589の筋萎縮性側索硬化症を対象とした探索的医師主導試験(EPIC-ALS),
第63回日本神経学会学術大会, 2022年5月. 安藤里英, 八木健太, 岡本尚大, 髙岡麻佑, 相澤風花, 濱野裕章, 石澤有紀, 合田光寛, 座間味義人, 石澤啓介 :
各種プロトンポンプ阻害剤のがん細胞におけるVEGF発現に与える影響,
日本薬学会第142年会, 2022年3月. 糸林小友理, 合田光寛, 吉田愛美, 杉本祐悟, 神田将哉, 吉岡俊彦, 櫻田巧, 相澤風花, 濱野裕章, 岡田直人, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの有効性の検証,
日本薬学会第142年会, 2022年3月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

相澤風花, 梶本春奈, 森山大嗣, 岡林亜美, 合田光寛, 濱野裕章, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
リアルワールドデータに基づく抗がん剤支持療法の開発;スタチン系薬剤による末梢神経障害治療および予防効果の検証,
第95回日本薬理学会年会, 2022年3月.

(キーワード): データ解析 (data analysis)

吉岡俊彦, 合田光寛, 神田将哉, 吉田愛美, 糸林小友理, 杉本祐悟, 石澤有紀, 八木健太, 相澤風花, 濱野裕章, 岡田直人, 座間味義人, 石澤啓介 :
シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの影響,
第95回日本薬理学会年会, 2022年3月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

阪本淑華, 友近七海, 濱野裕章, 合田光寛, 新村貴博, 相澤風花, 八木健太, 仲村明人, 西内栞, 石澤有紀, 座間味義人, 石澤啓介 :
大規模医療情報データベースを用いたスニチニブ誘発心不全に対する予防薬の探索,
第95回日本薬理学会年会, 2022年3月. 國木悠理香, 八木健太, 吉田莉奈, 岡本尚大, 安藤里英, 山川裕介, 濱野裕章, 合田光寛, 新村貴博, 相澤風花, 石澤有紀, 座間味義人, 石澤啓介 :
慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果,
第95回日本薬理学会年会, 2022年3月. 合田光寛, 神田将哉, 吉岡俊彦, 新村貴博, 櫻田巧, 小川敦, 岡田直人, 相澤風花, 八木健太, 濱野裕章, 石澤有紀, 座間味義人, 石澤啓介 :
医療ビッグデータ解析と基礎研究を融合した研究手法による抗がん剤誘発副作用に対する予防法の探索,
日本臨床腫瘍薬学会学術大会2022 シンポジウム 12, 2022年3月.

(キーワード): データ解析 (data analysis)

西内栞, 斎藤広海, 新村貴博, 座間味義人, 合田光寛, 八木健太, 相澤風花, 濱野裕章, 石澤有紀, 石澤啓介 :
ドキソルビシン誘発心筋症に対する予防薬探索を目的としたドラッグリポジショニング研究,
第42回日本臨床薬理学会学術総会, 2021年12月. 安藤里英, 八木健太, 岡本尚大, 相澤風花, 濱野裕章, 石澤有紀, 合田光寛, 座間味義人, 石澤啓介 :
ボノプラザンががん細胞のVEGF発現に与える影響に関する検討,
第140回日本薬理学会近畿部会, 2021年11月. 吉田愛美, 合田光寛, 杉本祐悟, 八木田ひかり, 神田将哉, 吉岡俊彦, 櫻田巧, 相澤風花, 濱野裕章, 岡田直人, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
シスプラチン誘発腎障害に対する新規予防候補薬の効果,
第140回日本薬理学会近畿部会, 2021年11月.

(キーワード): 腎疾患 (kidney disease) / データ解析 (data analysis)

大峯航平, 近藤正輝, 合田光寛, 西穂香, 宮田晃志, 辻中海斗, 濱野裕章, 相澤風花, 八木健太, 座間味義人, 石澤啓介, 石澤有紀 :
杜仲茶エキスによる大動脈疾患発症抑制効果の検討,
第140回日本薬理学会近畿部会, 2021年11月. 岡田直人, 中本亜樹, 泉侑希, 中馬真幸, 合田光寛, 八木健太, 相澤風花, 濱野裕章, 座間味義人, 東桃代, 石澤啓介 :
タゾバクタム・ピペラシリン併用時における血中濃度時間曲線下面積に基づくバンコマイシン誘発腎障害の評価,
第15回日本腎臓病薬物療法学会学術集会・総会2021, 2021年11月. 吉岡俊彦, 合田光寛, 神田将哉, 吉田愛美, 糸林小友理, 杉本祐悟, 石澤有紀, 八木健太, 相澤風花, 濱野裕章, 岡田直人, 座間味義人, 石澤啓介 :
シスプラチン誘発腎障害に対する杜仲葉エキスの効果,
第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2021年10月.

(キーワード): 腎疾患 (kidney disease) / データ解析 (data analysis)

吉田愛美, 合田光寛, 杉本祐悟, 八木田ひかり, 神田将哉, 吉岡俊彦, 櫻田巧, 石澤有紀, 相澤風花, 濱野裕章, 岡田直人, 八木健太, 座間味義人, 石澤啓介 :
シスプラチン誘発腎障害に対する新規予防薬の探索,
第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2021年10月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

谷友歩, 中馬真幸, 合田光寛, 坂東貴司, 近藤正輝, 國木悠理香, 濱野裕章, 新村貴博, 岡田直人, 相澤風花, 八木健太, 石澤啓介 :
ビッグデータ解析を活用したバンコマイシン関連腎障害に対する予防薬の探索とその有用性の検討,
第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2021年10月.

(キーワード): データ解析 (data analysis)

梶本春奈, 森山大嗣, 相澤風花, 新村貴博, 座間味義人, 合田光寛, 八木健太, 濱野裕章, 石澤有紀, 石澤啓介 :
FAERS解析を活用したオキサリプラチン誘発末梢神経障害に対する予防薬の検討,
第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2021年10月.

(キーワード): データ解析 (data analysis)

高橋志門, 武智研志, 定作奈津美, 濱野裕章, 相澤風花, 八木健太, 合田光寛, 石澤有紀, 石澤啓介 :
大規模医療情報データベースを用いたドラッグリポジショニングによるバラシクロビルの抗てんかん作用の検討,
第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2021年10月.

(キーワード): データ解析 (data analysis)

Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Nanami Tomochika, Shiori Nishiuchi, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yoshito Zamami and Keisuke Ishizawa :
Exploration of prophylactic drugs against doxorubicin-induced cardiomyopathy using largescale medical databases,
第15回次世代を担う若手のための医療薬科学シンポジウム, Oct. 2021. 辻中海斗, 岡田直人, 藤原範子, 合田光寛, 八木健太, 相澤風花, 濱野裕章, 櫻田巧, 桐野靖, 座間味義人, 東桃代, 石澤啓介 :
医療従事者におけるインフルエンザ暴露後予防目的におけるオセルタミビルのアドヒアランス解析,
第31回日本医療薬学会年会, 2021年10月. 岡田直人, 中本亜樹, 泉侑希, 中馬真幸, 合田光寛, 八木健太, 相澤風花, 濱野裕章, 座間味義人, 東桃代, 石澤啓介 :
タゾバクタム・ピペラシリン併用時のバンコマイシン誘発腎障害は血中濃度時間曲線下面積を指標とした TDMによって回避可能か?,
第31回日本医療薬学会年会, 2021年10月. 相澤風花, 梶本春奈, 森山大嗣, 新村貴博, 合田光寛, 新田綾香, 高橋志門, 濱野裕章, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
医療ビッグデータを基盤とした迅速かつ安全ながん支持療法の開発,
第31回日本医療薬学会年会, 2021年10月.

(キーワード): データ解析 (data analysis)

八木健太, 合田光寛, 濱野裕章, 坂口暁, 楊河宏章, 石澤啓介 :
臨床研究における倫理指針と個人情報の基礎知識,
第31回日本医療薬学会年会, 2021年10月. 座間味義人, 新村貴博, 濱野裕章, 合田光寛, 相澤風花, 八木健太, 石澤有紀, 石澤啓介 :
リアルワールドデータを活用したドラッグリポジショニング研究,
第31回日本医療薬学会年会, 2021年10月.

(キーワード): データ解析 (data analysis)

濱野裕章, 座間味義人, 合田光寛, 相澤風花, 八木健太, 石澤啓介 :
データサイエンスと基礎研究手法の融合,
第31回日本医療薬学会年会, 2021年10月.

(キーワード): データ解析 (data analysis)

中馬真幸, 中本亜樹, 坂東貴司, 新村貴博, 岡田直人, 相澤風花, 濱野裕章, 八木健太, 合田光寛, 座間味義人, 石澤啓介, 田崎嘉一 :
メタアナリシスとデータベース解析の融合によるハイインパクトエビデンスの創出,
第31回日本医療薬学会年会, 2021年10月.

(キーワード): データ解析 (data analysis)

神田将哉, 合田光寛, 吉岡俊彦, 吉田愛美, 新村貴博, 櫻田巧, 小川敦, 岡田直人, 相澤風花, 座間味義人, 八木健太, 濱野裕章, 石澤有紀, 石澤啓介 :
抗がん剤副作用予防のための大規模医療情報データベース解析を活用したリバーストランスレーショナルリサーチ,
第31回日本医療薬学会年会, 2021年10月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

合田光寛, 神田将哉, 吉岡俊彦, 吉田愛美, 新村貴博, 櫻田巧, 小川敦, 岡田直人, 相澤風花, 八木健太, 濱野裕章, 石澤有紀, 座間味義人, 石澤啓介 :
大規模医療情報データベースを活用した抗がん剤副作用に対する予防法の確立,
第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, 2021年10月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

辻中海斗, 石澤有紀, 新村貴博, 吉岡俊彦, 合田光寛, 近藤正輝, 大峯航平, 西穂香, 宮田晃志, 濱野裕章, 相澤風花, 八木健太, 座間味義人, 石澤啓介 :
血管新生阻害剤における大動脈解離発症の関連要因解明,
第50回日本心脈管作動物質学会, 2021年7月. 梶本春奈, 森山大嗣, 相澤風花, 新村貴博, 座間味義人, 合田光寛, 八木健太, 濱野裕章, 石澤有紀, 石澤啓介 :
オキサリプラチン誘発末梢神経障害に対するスタチン系薬剤の予防効果,
第139回日本薬理学会近畿部, 2021年6月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

谷友歩, 中馬真幸, 合田光寛, 坂東貴司, 近藤正輝, 國木悠理香, 濱野裕章, 新村貴博, 岡田直人, 相澤風花, 八木健太, 石澤有紀, 座間味義人, 石澤啓介 :
大規模医療情報および遺伝子発現データベースを活用したバンコマイシン関連腎障害に対する予防薬の探索とソの有用性の検討,
第139回日本薬理学会近畿部, 2021年6月.

(キーワード): データ解析 (data analysis) / 腎疾患 (kidney disease)

沖良祐, 和泉唯信, 藤田浩司, 佐藤康敬, 二見明香理, 前田和輝, 八木健太, 坂口暁, 楊河宏章, 桑原聡, 梶龍兒 :
COVID-19流行下におけるALSを対象とした医師主導治験運営の取組み,
第62回日本神経学会学術大会, 2021年5月. 神田将哉, 合田光寛, 吉岡俊彦, 吉田愛美, 新村貴博, 座間味義人, 石澤有紀, 八木健太, 濱野裕章, 岡田直人, 石澤啓介 :
シスプラチン誘発急性腎障害に対する各種5-HT3受容体拮抗薬併用の影響,
第94回日本薬理学会年会, 2021年3月. 相澤風花, 座間味義人, 新村貴博, 川尻雄大, 合田光寛, 八木健太, 石澤有紀, 石澤啓介 :
HMG-CoA還元酵素阻害剤はGSTを介してオキサリプラチン誘発末梢神経障害を抑制する,
第94回日本薬理学会年会, 2021年3月. 新村貴博, 座間味義人, 川尻雄大, 合田光寛, 相澤風花, 八木健太, 石澤有紀, 石澤啓介 :
基礎研究と臨床研究の融合による薬剤性末梢神経障害に対する予防薬探索,
日本薬学会第141年会, 2021年3月.

(キーワード): データ解析 (data analysis)

坂東貴司, 中馬真幸, 新村貴博, 座間味義人, 石澤有紀, 合田光寛, 八木健太, 濱野裕章, 岡田直人, 泉侑希, 桐野靖, 中村敏己, 石澤啓介 :
大規模医療情報データベースを活用したバンコマイシン関連腎障害に対する薬剤性腎障害原因薬剤の多剤併用における影響,
日本薬学会第141年会, 2021年3月.

(キーワード): データ解析 (data analysis)

相澤風花, 座間味義人, 濱野裕章, 岡田直人, 林明希, 八木健太, 合田光寛, 桐野靖, 中村敏己, 石澤啓介 :
COVID-19感染拡大に伴うオンライン型薬学実務実習の導入,
日本薬学会第141年会, 2021年3月. 相澤風花, 梶本春奈, 森山大嗣, 新村貴博, 座間味義人, 濱野裕章, 合田光寛, 八木健太, 石澤有紀, 石澤啓介 :
オキサリプラチン誘発末梢神経障害に対するHMG-CoA還元酵素阻害剤の影響,
第262回徳島医学会学術集会, 2021年3月. 合田光寛, 座間味義人, 新村貴博, 萱野純史, 濱野裕章, 岡田直人, 相澤風花, 八木健太, 石澤有紀, 桐野靖, 中村敏己, 石澤啓介 :
大規模医療情報データベースを活用した抗がん剤副作用予防のためのリバーストランスレーショナルリサーチ,
日本薬学会第140年会, 2021年3月. 阪本淑華, 座間味義人, 新村貴博, 相澤風花, 八木健太, 合田光寛, 石澤有紀, 石澤啓介 :
大規模医療情報データベースを用いたドキソルビシン誘発心筋症に対する予防薬の探索,
日本薬学会第141年会大学院生・学生シンポジウム, 2021年3月.

(キーワード): データ解析 (data analysis)

石澤啓介, 合田光寛, 中馬真幸, 八木健太, 石澤有紀, 座間味義人 :
有害事象自発報告データベースを活用した抗がん剤副作用に対する予防法の探索,
第41回日本臨床薬理学会学術総会学術委員会企画シンポジウム5, 2020年12月. 相澤風花, 合田光寛, 神田将哉, 吉岡俊彦, 吉田愛美, 新村貴博, 八木健太, 濱野裕章, 岡田直人, 座間味義人, 石澤有紀, 石澤啓介 :
シスプラチンと5-HT3受容体拮抗薬併用が腎機能障害に与える影響,
第30回日本循環薬理学会, 2020年11月. Yuki Izawa-Ishizawa, Yoshito Zamami, Niimura Takahiro, Mitsuhiro Goda, Kenta Yagi, Masayuki Chuma, Masaki Imanishi and Keisuke Ishizawa :
New strategy for Cardio-Oncology study; the combination of big data analysis and basic research,
第79回日本癌学会学術集会シンポジウム8, Oct. 2020.

研究会・報告書: 研究者総覧に該当データはありませんでした。

特許: 研究者総覧に該当データはありませんでした。
作品: 研究者総覧に該当データはありませんでした。
補助金・競争的資金: 抗VEGF療法の治療効果向上を目指した最適な支持療法薬の解明 (研究課題/領域番号: 24K09959 )
デジタルサイエンスを応用した抗がん剤関連性末梢神経障害治療薬の創出 (研究課題/領域番号: 24K09832 )
慢性骨髄性白血病再発防止を目指した新規治療法の開発 (研究課題/領域番号: 22K15340 )
性差を考慮したがん化学療法の確立―リアルワールドデータ駆動型薬理学研究 (研究課題/領域番号: 22K06863 )
データマイニングと疾患モデルによる感染症と大動脈疾患の包括的な連関解明 (研究課題/領域番号: 21H02646 )
シナジー効果の評価系構築と薬理的検証 (研究課題/領域番号: 20H05799 )
慢性骨髄性白血病再発防止を目指したALDH1A1阻害剤による治療戦略 (研究課題/領域番号: 20K16044 )
研究者番号（10869085）による検索

その他: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2025年6月27日更新

専門分野・研究分野: 医療薬学
臨床薬理学
薬理学
医療ビッグデータ
所属学会・所属協会: 研究者総覧に該当データはありませんでした。
委員歴・役員歴: 研究者総覧に該当データはありませんでした。
受賞: 研究者総覧に該当データはありませんでした。
活動: 研究者総覧に該当データはありませんでした。

リサーチマップで最新データを確認するＪグローバルで最新データを確認する

2025年6月29日更新

2025年6月28日更新

Ｊグローバル

Jグローバル最終確認日: 2025/6/28 01:18
氏名（漢字）: 八木健太
氏名（フリガナ）: JグローバルAPIで取得できませんでした。
氏名（英字）: Yagi Kenta
所属機関: 島根大学薬剤部准教授 / 副薬剤部長

リサーチマップ

researchmap最終確認日

2025/6/29 03:52

氏名（漢字）

八木健太

氏名（フリガナ）

リサーチマップAPIで取得できませんでした。

氏名（英字）

Yagi Kenta

プロフィール

＜認定・専門資格＞

日本臨床薬理学会指導薬剤師

日本医療薬学会　　医療薬学専門薬剤師

日本病院薬剤師会　病院薬学認定薬剤師

登録日時

2019/10/20 23:43

更新日時

2025/6/17 14:15

アバター画像URI

リサーチマップAPIで取得できませんでした。

ハンドル

リサーチマップAPIで取得できませんでした。

eメール

リサーチマップAPIで取得できませんでした。

eメール（その他）

リサーチマップAPIで取得できませんでした。

携帯メール

リサーチマップAPIで取得できませんでした。

性別

リサーチマップAPIで取得できませんでした。

没年月日

リサーチマップAPIで取得できませんでした。

所属ID

0512006000

所属

島根大学

部署

医学部附属病院

職名

薬剤部准教授 / 副薬剤部長

学位

博士（医学）

学位授与機関

岡山大学

URL

リサーチマップAPIで取得できませんでした。

科研費研究者番号

リサーチマップAPIで取得できませんでした。

Google Analytics ID

リサーチマップAPIで取得できませんでした。

ORCID ID

リサーチマップAPIで取得できませんでした。

その他の所属ID

リサーチマップAPIで取得できませんでした。

その他の所属名

リサーチマップAPIで取得できませんでした。

その他の所属部署

リサーチマップAPIで取得できませんでした。

その他の所属職名

リサーチマップAPIで取得できませんでした。

最近のエントリー

リサーチマップAPIで取得できませんでした。

Read会員ID

リサーチマップAPIで取得できませんでした。

経歴

受賞

Misc

論文

講演・口頭発表等

書籍等出版物

リサーチマップAPIで取得できませんでした。

研究キーワード

研究分野

所属学協会

リサーチマップAPIで取得できませんでした。

担当経験のある科目

リサーチマップAPIで取得できませんでした。

その他

リサーチマップAPIで取得できませんでした。

Works

リサーチマップAPIで取得できませんでした。

特許

リサーチマップAPIで取得できませんでした。

学歴

委員歴

社会貢献活動

リサーチマップAPIで取得できませんでした。

ＫＡＫＥＮで最新データを確認する

2025年6月28日更新

研究者番号: 10869085

所属（現在）: 2025/4/1 : 島根大学, 学術研究院医学・看護学系, 准教授

所属（過去の研究課題 情報に基づく）*注記: 2024/4/1 : 徳島大学, 病院, 特任講師
2020/4/1 – 2023/4/1 : 徳島大学, 病院, 特任助教

審査区分/研究分野

研究代表者

小区分47060:医療薬学関連

研究代表者以外

学術変革領域研究区分(Ⅳ)
小区分47060:医療薬学関連
小区分48030:薬理学関連
小区分47040:薬理学関連

キーワード

研究代表者

慢性骨髄性白血病 / 分子標的治療薬 / ALDH / がん幹細胞 / Bcr-Abl / 抗VEGF薬 / 支持療法薬 / プロトンポンプ阻害剤

研究代表者以外

薬剤シナジー効果 / 遺伝子発現データベース / オミックスデータベース / 病態モデル解析 / 遺伝子発言データベース / 大動脈解離 / 大動脈瘤 / 医療ビッグデータ / 感染症 / 抗菌薬 / リアルワールドデータベース / 薬物有害事象 / がん化学療法 / 性差医学 / 大動脈疾患 / 性差医療 / リアルワールドデータ / 有害事象 / 抗がん剤誘発性末梢神経障害 / 疼痛 / 抗悪性腫瘍剤 / データサイエンス / ドラッグリポジショニング

研究課題研究成果共同研究者

「研究課題をさがす」で表示
テキスト（CSV）で出力

テキスト（CSV）で出力

注目研究はありません。

研究者を探す

八木 健太

Ｊグローバル

リサーチマップ

研究代表者

研究代表者以外

研究代表者

研究代表者以外

八木健太